Effects of human OEC-derived cell transplants in rodent spinal cord	1
Effects	1
human OEC-derived cell transplants in rodent spinal cord	12
human OEC-derived cell transplants	12
rodent spinal cord	50
contusion injury	69
Catherine Anne Gorriea , , Ian Haywardb , Nicholas Cameronb , Gajan Kailainathana , Neilan Nandapalana , Ratneswary Sutharsanb , Jennifer Wanga , Alan Mackay-Simb , Phil M.E. Waitea aNeural Injury Research Unit , School of Medical Sciences , University	88
Catherine Anne Gorriea ,	88
Ian Haywardb	114
Nicholas Cameronb	128
Gajan Kailainathana	147
Neilan Nandapalana	168
Ratneswary Sutharsanb	188
Jennifer Wanga	211
Alan Mackay-Simb	227
Phil M.E. Waitea aNeural Injury Research Unit	245
School of Medical Sciences	292
School	292
Medical Sciences	302
University	320
New South Wales , Sydney , NSW , 2052 , Australia bNational Centre for Adult Stem Cell Research , Griffith University , Brisbane , QLD 4111 , Australia Abstract	334
New South Wales	334
Sydney	351
NSW	359
2052	364
Australia bNational Centre for Adult Stem Cell Research , Griffith University , Brisbane , QLD 4111	370
Australia bNational Centre	370
Adult Stem Cell Research , Griffith University , Brisbane , QLD 4111	401
Adult Stem Cell Research	401
Griffith University , Brisbane , QLD 4111	427
Australia Abstract	468
Numerous reports	489
rodent olfactory ensheathing cells -LRB- OECs -RRB-	520
rodent olfactory ensheathing cells	520
OECs	556
spinal cord repair	572
clinical trials	595
autologous transplantation of human olfactory ensheathing cells -LRB- hOECs -RRB-	638
autologous transplantation	638
human olfactory ensheathing cells -LRB- hOECs -RRB-	668
human olfactory ensheathing cells	668
hOECs	703
a treatment for spinal cord injury	713
a treatment	713
spinal cord injury	729
there	758
few studies investigating the efficacy of hOECs in animal models of spinal cord injury	768
few studies	768
the efficacy of hOECs in animal models of spinal cord injury	794
the efficacy	794
hOECs in animal models of spinal cord injury	810
hOECs	810
animal models of spinal cord injury	819
animal models	819
spinal cord injury	836
this study	859
hOECs	870
biopsies of human olfactory mucosa	894
biopsies	894
human olfactory mucosa	906
culture	941
a serum-free medium containing neurotrophin-3	952
a serum-free medium	952
neurotrophin-3	983
EGFP	1025
These hOEC-derived cells	1050
the spinal cord injury site 7 days	1109
the spinal cord injury site	1109
7 days	1137
a moderate contusion injury of the spinal cord	1150
a moderate contusion injury	1150
the spinal cord	1181
thoracic level T10 in the athymic rat	1200
thoracic level T10	1200
the athymic rat	1222
Six weeks later	1239
the animals receiving the hOEC-derived transplants had greater functional improvement in their hindlimbs than controls , assessed using open field -LRB- BBB scale -RRB- and horizontal	1255
the animals	1255
the hOEC-derived transplants	1277
greater functional improvement	1310
their hindlimbs	1344
controls	1365
open field -LRB- BBB scale -RRB-	1390
open field	1390
BBB scale	1402
tests	1441
Histological analysis	1448
beneficial effects of hOEC-derived cell transplantation : reductions in the volume of the lesion and the cavities within the lesion	1483
beneficial effects of hOEC-derived cell transplantation : reductions in the volume of the lesion	1483
beneficial effects of hOEC-derived cell transplantation	1483
beneficial effects	1483
hOEC-derived cell transplantation	1505
reductions in the volume of the lesion	1540
reductions	1540
the volume of the lesion	1554
the volume	1554
the lesion	1568
the cavities within the lesion	1583
the cavities	1583
the lesion	1603
The transplanted cells	1615
the periphery of the lesion	1654
the periphery	1654
the lesion	1671
they	1688
GFAP-positive astrocytes resulting in a significant reduction of GFAP staining intensity adjacent to the lesion	1709
GFAP-positive astrocytes	1709
a significant reduction of GFAP staining intensity adjacent to the lesion	1747
a significant reduction	1747
GFAP staining intensity adjacent to the lesion	1774
GFAP staining intensity	1774
the lesion	1810
their mechanism of action	1831
their mechanism	1831
action	1850
we	1868
hOEC-derived cell transplants	1885
functional recovery	1924
transplantation	1950
the contused spinal cord , probably by modulating inflammatory responses and reducing secondary damage to the cord	1971
the	1971
spinal cord	1984
inflammatory responses	2020
secondary damage	2056
the cord	2076
Introduction Traumatic spinal cord injury	2090
Introduction	2090
Traumatic spinal cord injury	2103
a complex , progressive event leading to long-term motor and sensory deficits , and dysfunction of the autonomic nervous system	2135
a complex , progressive event leading to long-term motor and sensory deficits	2135
a complex , progressive event leading	2135
long-term motor and sensory deficits	2175
dysfunction of the autonomic nervous system	2217
dysfunction	2217
the autonomic nervous system	2232
the spinal cord	2265
there	2281
cell death	2290
axons , demyelination , inflammation and the formation of cystic cavities -LRB- Sekhon and Fehlings , 2001 -RRB-	2314
axons	2314
demyelination	2321
inflammation	2336
the formation of cystic cavities -LRB- Sekhon and Fehlings , 2001 -RRB-	2353
the formation	2353
cystic cavities -LRB- Sekhon and Fehlings , 2001 -RRB-	2370
cystic cavities	2370
Sekhon and Fehlings	2387
2001	2408
There	2415
limited capacity of the human spinal cord to repair itself	2424
limited capacity	2424
the human spinal cord	2444
itself	2476
there	2487
a need for therapeutic strategies to protect and repair the injured spinal cord	2496
a need	2496
therapeutic strategies	2507
the injured spinal cord	2552
Olfactory ensheathing cells -LRB- OECs -RRB-	2577
Olfactory ensheathing cells	2577
OECs	2606
a unique type of glial cell that share some properties with astrocytes and Schwann cells but have intrinsic properties that make them ideal candidates for cellular grafts into injured spinal tissue -LRB- Chuah and Au , 1994 ; Fairless and Barnett , 2005 ; Farbman and Squinto , 1985 ; Ramon-Cueto and Valverde , 1995 -RRB-	2616
a unique type	2616
glial cell that share some properties with astrocytes and Schwann cells but have intrinsic properties that make them ideal candidates for cellular grafts into injured spinal tissue -LRB- Chuah and Au , 1994 ; Fairless and Barnett , 2005 ; Farbman and Squinto , 1985 ; Ramon-Cueto and Valverde , 1995 -RRB-	2633
glial cell	2633
some properties	2655
astrocytes and Schwann cells	2676
intrinsic properties that make them ideal candidates for cellular grafts into injured spinal tissue	2714
intrinsic properties	2714
them	2745
ideal candidates for cellular grafts	2750
ideal candidates	2750
cellular grafts	2771
injured spinal tissue	2792
Chuah and Au , 1994 ; Fairless and Barnett , 2005 ; Farbman and Squinto , 1985 ; Ramon-Cueto and Valverde , 1995	2815
Chuah and Au	2815
1994 ; Fairless and Barnett , 2005 ; Farbman and Squinto , 1985 ; Ramon-Cueto and Valverde	2829
1994	2829
Fairless and Barnett , 2005 ; Farbman and Squinto , 1985 ; Ramon-Cueto and Valverde	2835
Fairless and Barnett , 2005	2835
Fairless and Barnett	2835
2005	2857
Farbman and Squinto , 1985	2863
Farbman and Squinto	2863
1985	2884
Ramon-Cueto and Valverde	2890
Ramon-Cueto	2890
Valverde	2906
1995	2916
Many studies	2923
OECs	2959
the injured spinal cord in rodent models including restoration of motor function -LRB- Keyvan - Fouladi et al. , 2003 ; Kubasak et al. , 2008 ; Li et al. , 2003 ; Li et al. , 1997 ; Lopez-Vales et al. , 2007 -RRB- , improvement of respiratory function -LRB- Li et al. , 2003 -RRB- and restoration of bladder function -LRB- Pascual et al. , 2002 -RRB-	3003
the injured spinal cord	3003
rodent models including restoration of motor function -LRB- Keyvan - Fouladi et al. , 2003 ; Kubasak et al. , 2008 ; Li et al. , 2003 ; Li et al. , 1997 ; Lopez-Vales et al. , 2007 -RRB- , improvement of respiratory function -LRB- Li et al. , 2003 -RRB- and restoration of bladder function -LRB- Pascual et al. , 2002 -RRB-	3030
rodent models	3030
restoration of motor function -LRB- Keyvan - Fouladi et al. , 2003 ; Kubasak et al. , 2008 ; Li et al. , 2003 ; Li et al. , 1997 ; Lopez-Vales et al. , 2007 -RRB- , improvement of respiratory function -LRB- Li et al. , 2003 -RRB- and restoration of bladder function -LRB- Pascual et al. , 2002 -RRB-	3054
restoration of motor function -LRB- Keyvan - Fouladi et al. , 2003 ; Kubasak et al. , 2008 ; Li et al. , 2003 ; Li et al. , 1997 ; Lopez-Vales et al. , 2007 -RRB-	3054
restoration	3054
motor function -LRB- Keyvan - Fouladi et al. , 2003 ; Kubasak et al. , 2008 ; Li et al. , 2003 ; Li et al. , 1997 ; Lopez-Vales et al. , 2007 -RRB-	3069
motor function	3069
Keyvan	3085
Fouladi et al. , 2003 ; Kubasak et al. , 2008 ; Li et al. , 2003 ; Li et al. , 1997 ; Lopez-Vales et al. , 2007	3093
Fouladi	3093
et al. , 2003 ; Kubasak et al. , 2008 ; Li et al. , 2003 ; Li et al. , 1997 ; Lopez-Vales et al. , 2007	3101
et al. , 2003	3101
et al.	3101
2003	3109
Kubasak et al. , 2008	3115
Kubasak	3115
et al. , 2008	3123
et al.	3123
2008	3131
Li et al. , 2003	3137
Li	3137
et al. , 2003	3140
et al.	3140
2003	3148
Li et al. , 1997	3154
Li	3154
et al. , 1997	3157
et al.	3157
1997	3165
Lopez-Vales et al. , 2007	3171
Lopez-Vales	3171
et al. , 2007	3183
et al.	3183
2007	3191
improvement of respiratory function -LRB- Li et al. , 2003 -RRB-	3198
improvement	3198
respiratory function -LRB- Li et al. , 2003 -RRB-	3213
respiratory function	3213
Li	3235
et al. , 2003	3238
et al.	3238
2003	3246
restoration of bladder function -LRB- Pascual et al. , 2002 -RRB-	3256
restoration	3256
bladder function -LRB- Pascual et al. , 2002 -RRB-	3271
bladder function	3271
Pascual	3289
et al. , 2002	3297
et al.	3297
2002	3305
OECs	3325
axon regeneration -LRB- Keyvan-Fouladi et al. , 2003 ; Li et al. , 1997 , 1998 , 2007 ; Lopez-Vales et al. , 2007 ; Plant et al. , 2003 ; Ramon-Cueto et al. , 1998 -RRB- , remyelination of axons -LRB- Barnett et al. , 2000 ; Imaizumi et al. , 1998 ; Kato et al. , 2000 -RRB- ,	3338
axon regeneration	3338
Keyvan-Fouladi et al. , 2003 ; Li et al. , 1997 , 1998 , 2007 ; Lopez-Vales et al. , 2007 ; Plant et al. , 2003 ; Ramon-Cueto et al. , 1998	3357
Keyvan-Fouladi	3357
et al. , 2003 ; Li et al. , 1997 , 1998 , 2007 ; Lopez-Vales et al. , 2007 ; Plant et al. , 2003 ; Ramon-Cueto et al. , 1998	3372
et al. , 2003	3372
et al.	3372
2003	3380
Li et al. , 1997 , 1998 , 2007	3386
Li	3386
et al. , 1997 , 1998 , 2007	3389
et al.	3389
1997	3397
1998	3403
2007	3409
Lopez-Vales et al. , 2007	3415
Lopez-Vales	3415
et al. , 2007	3427
et al.	3427
2007	3435
Plant et al. , 2003	3441
Plant	3441
et al. , 2003	3447
et al.	3447
2003	3455
Ramon-Cueto et al. , 1998	3461
Ramon-Cueto	3461
et al. , 1998	3473
et al.	3473
1998	3481
remyelination of axons -LRB- Barnett et al. , 2000 ; Imaizumi et al. , 1998 ; Kato et al. , 2000 -RRB-	3488
remyelination	3488
axons -LRB- Barnett et al. , 2000 ; Imaizumi et al. , 1998 ; Kato et al. , 2000 -RRB-	3505
axons	3505
Barnett et al. , 2000 ; Imaizumi et al. , 1998 ; Kato et al. , 2000	3512
Barnett	3512
et al. , 2000 ; Imaizumi et al. , 1998 ; Kato et al. , 2000	3520
et al. , 2000	3520
et al.	3520
2000	3528
Imaizumi et al. , 1998	3534
Imaizumi	3534
et al. , 1998	3543
et al.	3543
1998	3551
Kato et al. , 2000	3557
Kato	3557
et al. , 2000	3562
et al.	3562
2000	3570
lesion size , cystic cavitation and astrocytic gliosis -LRB- Lopez-Vales et al. , 2006 ; Ramer et al. , 2004 ; Takami et al. , 2002 ; Verdu et al. , 2001 -RRB-	3585
lesion size	3585
cystic cavitation	3598
astrocytic gliosis -LRB- Lopez-Vales et al. , 2006 ; Ramer et al. , 2004 ; Takami et al. , 2002 ; Verdu et al. , 2001 -RRB-	3620
astrocytic gliosis	3620
Lopez-Vales et al. , 2006 ; Ramer et al. , 2004 ; Takami et al. , 2002 ; Verdu et al. , 2001	3640
Lopez-Vales	3640
et al. , 2006 ; Ramer et al. , 2004 ; Takami et al. , 2002 ; Verdu et al. , 2001	3652
et al. , 2006	3652
et al.	3652
2006	3660
Ramer et al. , 2004	3666
Ramer	3666
et al. , 2004	3672
et al.	3672
2004	3680
Takami et al. , 2002	3686
Takami	3686
et al. , 2002	3693
et al.	3693
2002	3701
Verdu et al. , 2001	3707
Verdu	3707
et al. , 2001	3713
et al.	3713
2001	3721
electrical conduction	3743
the injury site -LRB- Imaizumi et al. , 1998 , 2000 ; Lopez-Vales et al. , 2006 , 2007 ; Toft et al. , 2007 -RRB-	3773
the injury site	3773
Imaizumi	3790
et al. , 1998 , 2000 ; Lopez-Vales et al. , 2006 , 2007 ; Toft et al. , 2007	3799
et al.	3799
1998 , 2000 ; Lopez-Vales et al. , 2006 , 2007 ; Toft et al.	3807
1998 , 2000	3807
1998	3807
2000	3813
Lopez-Vales et al. , 2006 , 2007	3819
Lopez-Vales	3819
et al. , 2006 , 2007	3831
et al.	3831
2006	3839
2007	3845
Toft et al.	3851
Toft	3851
et al.	3856
2007	3864
Most previous studies	3871
the therapeutic properties of rat OECs	3911
the therapeutic properties	3911
rat OECs	3941
human OECs remyelinated spinal cord axons after demyelinating lesions -LRB- Barnett et al. , 2000 ; Kato et al. , 2000 -RRB- and primate OECs	3959
human OECs	3959
spinal cord axons	3983
demyelinating lesions -LRB- Barnett et al. , 2000 ; Kato et al. , 2000 -RRB- and primate OECs	4007
demyelinating lesions -LRB- Barnett et al. , 2000 ; Kato et al. , 2000 -RRB-	4007
demyelinating lesions	4007
Barnett	4030
et al. , 2000 ; Kato et al. , 2000	4038
et al.	4038
2000 ; Kato et al.	4046
2000	4046
Kato et al.	4052
Kato	4052
et al.	4057
2000	4065
primate OECs	4075
locomotor recovery	4096
transection injury	4121
the rat -LRB- Guest et al. , 2008 -RRB-	4143
the rat	4143
Guest	4152
et al. , 2008	4158
et al.	4158
2008	4166
There	4173
no previous studies of human OEC transplantation	4183
no previous studies	4183
human OEC transplantation	4206
the contused rat spinal cord	4237
a model of injury that mimics aspects of many common human injuries	4267
a model	4267
injury	4278
aspects of many common human injuries	4297
aspects	4297
many common human injuries	4308
Most previous studies , including the human and primate reports ,	4336
Most previous studies	4336
the human and primate reports	4369
OECs	4409
the olfactory bulbs	4419
the cranial cavity	4446
This	4466
a clinically favoured site for sourcing autologous OECs because of the morbidity associated with surgical access and destruction of the olfactory bulbs to obtain the cells	4478
a clinically favoured site	4478
sourcing autologous OECs because of the morbidity associated with surgical access and destruction of the olfactory bulbs to obtain the cells	4509
sourcing autologous OECs	4509
the morbidity associated with surgical access and destruction of the olfactory bulbs to obtain the cells	4545
the morbidity	4545
surgical access and destruction of the olfactory bulbs	4575
surgical access and destruction	4575
the olfactory bulbs	4610
the cells	4640
OECs	4651
the olfactory mucosa in the nose -LRB- Bianco et al. , 2004 -RRB-	4677
the olfactory mucosa	4677
the nose -LRB- Bianco et al. , 2004 -RRB-	4701
the nose	4701
Bianco	4711
et al. , 2004	4718
et al.	4718
2004	4726
OECs from this source	4736
OECs	4736
this source	4746
the transected spinal cord in rat -LRB- Lu et al. , 2001 , 2002 -RRB-	4798
the transected spinal cord	4798
rat -LRB- Lu et al. , 2001 , 2002 -RRB-	4828
rat	4828
Lu	4833
et al. , 2001 , 2002	4836
et al.	4836
2001	4844
2002	4850
hOECs derived from the olfactory mucosa	4857
hOECs	4857
the olfactory mucosa	4876
rat nasal OECs in proliferation , survival and migration	4913
rat nasal OECs	4913
proliferation , survival and migration	4931
transplantation	4975
the normal spinal cord of athymic rats -LRB- Deng et al. , 2006 -RRB-	4996
the normal spinal cord	4996
athymic rats -LRB- Deng et al. , 2006 -RRB-	5022
athymic rats	5022
Deng	5036
et al. , 2006	5041
et al.	5041
2006	5049
autologous transplants	5060
OECs	5084
the human nose	5124
biopsy of the olfactory mucosa	5142
biopsy	5142
the olfactory mucosa	5152
olfactory function -LRB- Feron et al. , 1998 -RRB-	5192
olfactory function	5192
Feron	5212
et al. , 1998	5218
et al.	5218
1998	5226
A Phase I clinical trial	5233
A Phase I	5233
A Phase	5233
I	5241
clinical trial	5243
transplantation of autologous OECs	5276
transplantation	5276
autologous OECs	5295
human paraplegia -LRB- Feron et al. , 2005 ; Mackay-Sim et al. , 2008 -RRB-	5323
human paraplegia	5323
Feron	5341
et al. , 2005 ; Mackay-Sim et al. , 2008	5347
et al.	5347
2005 ; Mackay-Sim et al.	5355
2005	5355
Mackay-Sim et al.	5361
Mackay-Sim	5361
et al.	5372
2008	5380
The aim of this study	5387
The aim	5387
this study	5398
OECs obtained from the human mucosa and genetically labelled with green fluorescent protein	5434
OECs	5434
the human mucosa	5453
green fluorescent protein	5500
similar behavioural outcomes	5546
that reported for rat OECs	5578
that	5578
rat OECs	5596
the remyelination potential of human bulbar OECs	5612
the remyelination potential	5612
human bulbar OECs	5643
this	5682
the first time locomotor improvements following human mucosal OEC transplants have been investigated	5690
the first time	5690
locomotor improvements following human mucosal OEC transplants	5705
locomotor improvements	5705
human mucosal OEC transplants	5738
We	5792
the traumatic contusion model -LRB- MASCIS impactor -RRB- which results in a complex central lesion with damage to spinal cord tissue and blood vessels	5800
the traumatic contusion model	5800
MASCIS impactor	5831
a complex central lesion with damage	5865
a complex central lesion	5865
damage	5895
spinal cord tissue and blood vessels	5905
ongoing secondary injury and cyst formation -LRB- Basso et al. , 1996 -RRB-	5947
ongoing secondary injury	5947
cyst formation -LRB- Basso et al. , 1996 -RRB-	5976
cyst formation	5976
Basso	5992
et al. , 1996	5998
et al.	5998
1996	6006
human spinal injury -LRB- Sekhon and Fehlings , 2001 -RRB-	6023
human spinal injury	6023
Sekhon and Fehlings	6044
2001	6065
The use of athymic rats -LRB- Rolstad , 2001 -RRB-	6072
The use	6072
athymic rats -LRB- Rolstad , 2001 -RRB-	6083
athymic rats	6083
Rolstad	6097
2001	6106
xenograft rejection of the hOECs	6119
xenograft rejection	6119
the hOECs	6142
transplantation	6166
a week	6188
injury	6201
exposure of the grafted cells to the acute inflammatory phase	6216
exposure	6216
the grafted cells to the acute inflammatory phase	6228
the grafted cells	6228
the acute inflammatory phase	6249
Results	6283
1	6296
Human OEC transplantation	6300
locomotor behaviour	6335
-LRB- A -RRB- hOECs transplantation -LRB- triangles -RRB- at 1 week after contusion injury	6356
-LRB- A -RRB- hOECs transplantation	6356
-LRB- A -RRB- hOECs	6356
A	6357
transplantation	6366
triangles	6383
1 week after contusion injury	6397
1 week	6397
contusion injury	6410
locomotor recovery measured using the BBB open field scores compared to controls -LRB- circles -RRB- , -LRB- repeated measures ANOVA , -LRB- F -LRB- 1,18 -RRB- = 9.6 , p = 0.006 -RRB- -RRB-	6450
locomotor recovery	6450
the BBB open field scores	6484
controls -LRB- circles -RRB-	6522
controls	6522
circles	6532
measures	6552
ANOVA , -LRB- F -LRB- 1,18 -RRB- = 9.6 , p = 0.006 -RRB-	6561
ANOVA	6561
F -LRB- 1,18 -RRB- = 9.6 , p	6569
F -LRB- 1,18 -RRB-	6569
F	6569
1,18	6572
9.6 , p	6578
9.6	6578
p	6583
0.006	6585
Bonferroni	6594
hoc tests show significant increases in the OEC group by 4 weeks post injury	6610
hoc	6610
tests	6614
significant increases in the OEC group	6625
significant increases	6625
the OEC group	6650
4 weeks post injury	6667
4 weeks	6667
-LRB- B -RRB- hOEC transplantation -LRB- dark bar -RRB-	6688
-LRB- B -RRB- hOEC transplantation	6688
-LRB- B -RRB-	6688
hOEC transplantation	6692
dark bar	6714
fewer stepping errors than the controls -LRB- light bar -RRB- during the horizontal ladder task , *	6736
fewer stepping errors	6736
the controls -LRB- light bar -RRB- during the horizontal ladder task	6763
the controls -LRB- light bar -RRB-	6763
the controls	6763
light bar	6777
the horizontal ladder task	6795
p = 0.05	6824
p	6824
0.05	6826
Scores	6833
means and SEM	6849
Fig. 2 -- Human OEC transplantation and the lesion site .	6866
Fig. 2	6866
Human OEC transplantation and the lesion site	6875
Human OEC transplantation	6875
the lesion site	6905
-LRB- A , B -RRB- Horizontal sections	6922
A , B	6923
A	6923
B	6926
spinal cord	6952
H&E	6977
the lesion site	6989
5 weeks	7005
A	7020
control medium injection or -LRB- B -RRB- hOEC transplantation	7023
control medium injection	7023
B	7052
hOEC transplantation	7055
Large dotted box	7077
the total area	7100
the spinal cord	7128
Smaller dotted region	7160
Smaller	7160
region	7175
the lesion area	7188
cavities -LRB- * -RRB- and cell debris	7209
cavities -LRB- * -RRB-	7209
cavities	7209
cell debris	7226
-LRB- C -- E -RRB- High power images from the boxed areas in A and B. -LRB- C -RRB- The penumbra of the lesion showing the peripheral white matter -LRB- wm -RRB- .	7239
-LRB- C -- E -RRB- High power	7239
C -- E	7240
C	7240
E	7242
images from the boxed areas in A and B. -LRB- C -RRB- The penumbra of the lesion showing the peripheral white matter -LRB- wm -RRB-	7256
images	7256
the boxed areas in A and B. -LRB- C -RRB- The penumbra of the lesion showing the peripheral white matter -LRB- wm -RRB-	7268
the	7268
areas in A and B. -LRB- C -RRB- The penumbra of the lesion showing the peripheral white matter -LRB- wm -RRB-	7278
areas	7278
A and B.	7287
A	7287
B.	7293
C	7297
The penumbra of the lesion showing the peripheral white matter -LRB- wm -RRB-	7300
The penumbra	7300
the lesion showing the peripheral white matter -LRB- wm -RRB-	7316
the lesion	7316
the peripheral white matter -LRB- wm -RRB-	7335
the peripheral white matter	7335
wm	7364
-LRB- D -RRB- The centre of the lesion in the control animal containing cell debris , macrophages , and trabeculae of spinal tissue extending into the lesion -LRB- long arrows -RRB- .	7369
-LRB- D -RRB- The centre of the lesion in the control animal containing cell debris , macrophages , and trabeculae	7369
The centre	7373
the lesion in the control animal containing cell debris , macrophages , and trabeculae	7387
the lesion	7387
the control animal containing cell debris , macrophages , and trabeculae	7401
the control animal	7401
cell debris , macrophages , and trabeculae	7431
cell debris	7431
macrophages	7444
trabeculae	7461
spinal tissue extending into the lesion -LRB- long arrows -RRB-	7475
spinal tissue	7475
the lesion -LRB- long arrows -RRB-	7504
the lesion	7504
long arrows	7516
-LRB- E -RRB- The centre of the lesion in the hOEC transplanted animal .	7530
-LRB- E -RRB- The centre of the lesion in the hOEC	7530
-LRB- E -RRB-	7530
The centre of the lesion in the hOEC	7534
The centre	7534
the lesion in the hOEC	7548
the lesion	7548
the hOEC	7562
animal	7584
Fig. 3 -- Transplanted hOECs reduced lesion size , cavity area and increased tissue sparing .	7593
Fig. 3	7593
hOECs	7615
lesion	7629
size , cavity area	7636
tissue sparing	7668
Measurements , expressed as percentages ,	7684
Measurements	7684
percentages	7711
the spinal cord	7741
the dorsal -LRB- left -RRB-	7762
the dorsal	7762
left	7774
the ventral -LRB- right -RRB- surface	7783
-LRB- A -RRB- Lesion area is highest in the dorsal spinal cord and transplanted hOECs	7812
-LRB- A -RRB-	7812
Lesion area	7816
highest in the dorsal spinal cord and transplanted hOECs	7831
highest	7831
the dorsal spinal cord and transplanted hOECs	7842
the dorsal spinal cord	7842
transplanted hOECs	7869
lesion size	7896
-LRB- B -RRB- The cavity area within the lesion was highest in the middle of the spinal cord and reduced in the hOEC transplanted animals compared to the controls .	7919
-LRB- B -RRB- The cavity area within the lesion was highest in the middle of the spinal cord and reduced in the hOEC	7919
-LRB- B -RRB-	7919
The cavity area within the lesion	7923
The cavity area	7923
the lesion	7946
the middle of the spinal cord	7972
the middle	7972
the spinal cord	7986
the hOEC	8017
transplanted animals compared to the controls	8026
transplanted animals	8026
the controls	8059
C	8074
Tissue sparing	8077
Tissue	8077
dorsal	8107
ventral cord	8117
both groups	8134
there	8155
differential sparing of tissue for the hOEC transplanted animals	8165
differential sparing	8165
tissue for the hOEC transplanted animals	8189
the hOEC	8200
hOEC transplants	8234
the GFAP intensity	8259
the lesion	8290
p < 0.05 .	8303
p	8303
< 0.05 .	8304
<	8304
0.05 .	8305
Fig. 4 -- Transplanted hOECs remained within the lesion .	8312
Fig. 4	8312
hOECs	8334
the lesion	8356
Horizontal sections of spinal cord 5 weeks after hOEC transplantation .	8368
Horizontal sections	8368
spinal cord 5 weeks	8391
spinal cord	8391
5 weeks	8403
hOEC transplantation	8417
-LRB- A -RRB- GFP labelled hOECs -LRB- green -RRB-	8439
-LRB- A -RRB-	8439
GFP	8443
hOECs	8456
the lesion	8489
the periphery of the lesion -LRB- dotted line -RRB-	8521
the periphery	8521
the lesion -LRB- dotted line -RRB-	8538
the lesion	8538
line	8557
Yellow cells -LRB- arrows -RRB-	8564
Yellow cells	8564
arrows	8578
autofluorescent macrophages seen in similar numbers in hOEC transplanted and control sections	8590
autofluorescent macrophages	8590
similar numbers in hOEC	8626
similar numbers	8626
hOEC	8645
transplanted and control sections	8650
transplanted	8650
control sections	8667
-LRB- B -RRB- High power image of the GFP	8685
-LRB- B -RRB- High power image	8685
-LRB- B -RRB- High power	8685
B	8686
the GFP	8709
hOECs -LRB- green -RRB-	8726
hOECs	8726
their morphology and rostro-caudal orientation	8748
-LRB- C -RRB- Rarely , hOECs -LRB- open arrow -RRB-	8796
-LRB- C -RRB- Rarely	8796
-LRB- C -RRB-	8796
hOECs -LRB- open arrow -RRB-	8808
hOECs	8808
open arrow	8815
the parenchyma surrounding the lesion -LRB- dotted line shows lesion edge , solid line shows spinal cord edge -RRB-	8840
the parenchyma	8840
the lesion	8867
line	8886
lesion edge	8897
solid line	8910
spinal cord edge	8927
F	8952
images of the same section viewed with -LRB- D -RRB- green filter only , -LRB- E -RRB- red filter only and -LRB- F -RRB- merged , demonstrating the autofluorescent cells -LRB- open arrows , yellow -RRB- in the center of the lesion , with hOEC -LRB- closed arrows , green -RRB- clearly distinguishable	8958
images	8958
the same section	8968
-LRB- D -RRB- green filter only , -LRB- E -RRB- red filter only	8997
-LRB- D -RRB- green filter only	8997
-LRB- D -RRB- green filter	8997
D	8998
-LRB- E -RRB- red filter	9020
E	9021
F	9045
the autofluorescent cells -LRB- open arrows , yellow -RRB- in the center of the lesion , with hOEC -LRB- closed arrows , green -RRB- clearly distinguishable	9070
the autofluorescent cells -LRB- open arrows , yellow -RRB-	9070
the autofluorescent cells	9070
open arrows , yellow	9097
open arrows	9097
yellow	9110
the center	9121
the lesion	9135
hOEC -LRB- closed arrows , green -RRB-	9152
hOEC	9152
closed arrows , green	9158
closed arrows	9158
green	9173
These autofluorescent cells	9205
the control sections	9251
Fig. 5 -- Cellular interactions of transplanted hOECs .	9274
Fig. 5	9274
Cellular interactions of transplanted hOECs	9283
Cellular interactions	9283
transplanted hOECs	9308
Horizontal sections of spinal cord tissue 5 weeks after hOEC transplantation .	9328
Horizontal sections	9328
spinal cord tissue 5 weeks	9351
spinal cord tissue	9351
5 weeks	9370
hOEC transplantation	9384
-LRB- A -RRB- High levels of GFAP staining -LRB- red -RRB- immediately adjacent to the lesion -LRB- dotted line -RRB- in a control spinal cord .	9406
-LRB- A -RRB- High levels of GFAP staining -LRB- red -RRB-	9406
-LRB- A -RRB- High levels of GFAP staining	9406
-LRB- A -RRB-	9406
High levels of GFAP staining	9410
High levels	9410
GFAP staining	9425
red	9440
the lesion -LRB- dotted line -RRB- in a control spinal cord	9469
the lesion -LRB- dotted line -RRB-	9469
the lesion	9469
line	9488
a control spinal cord	9497
-LRB- B -RRB- Reduced GFAP staining intensity adjacent to the lesion in a hOECs transplanted spinal cord .	9520
-LRB- B -RRB-	9520
GFAP staining intensity	9532
the lesion in a hOECs transplanted spinal cord	9568
the lesion	9568
a hOECs transplanted spinal cord	9582
-LRB- C -RRB- At the lesion interface hOECs -LRB- green , arrow -RRB- and astrocytic process -LRB- red , open arrowhead -RRB-	9616
-LRB- C -RRB-	9616
the lesion	9623
interface hOECs -LRB- green , arrow -RRB- and astrocytic process -LRB- red , open arrowhead -RRB-	9634
interface hOECs -LRB- green , arrow -RRB-	9634
interface hOECs	9634
green , arrow	9651
green	9651
arrow	9658
astrocytic process -LRB- red , open arrowhead -RRB-	9669
astrocytic process	9669
red , open arrowhead	9689
red	9689
open arrowhead	9694
close proximity	9723
-LRB- D -RRB- NF-200 staining of axons in the peripheral white matter showing large axons with apparent retraction balls -LRB- open arrow -RRB- and terminal bulbs -LRB- closed arrow -RRB- .	9740
-LRB- D -RRB- NF-200 staining of axons in the peripheral white matter	9740
NF-200 staining	9744
axons in the peripheral white matter	9763
axons	9763
the peripheral white matter	9772
large axons	9808
apparent retraction balls -LRB- open arrow -RRB- and terminal bulbs -LRB- closed arrow -RRB-	9825
apparent retraction balls -LRB- open arrow -RRB-	9825
apparent retraction balls	9825
open arrow	9852
terminal bulbs -LRB- closed arrow -RRB-	9868
terminal bulbs	9868
arrow	9891
-LRB- E -RRB- Confocal image showing hOECs -LRB- green , arrows -RRB- located in close association with NF200-positive axons -LRB- red , arrowheads -RRB- at the periphery of the lesion .	9899
-LRB- E -RRB- Confocal image	9899
-LRB- E -RRB-	9899
Confocal image	9903
hOECs -LRB- green , arrows -RRB- located in close association with NF200-positive axons -LRB- red , arrowheads -RRB-	9926
hOECs	9926
green , arrows	9933
green	9933
arrows	9940
close association with NF200-positive axons -LRB- red , arrowheads -RRB-	9959
close association	9959
NF200-positive axons -LRB- red , arrowheads -RRB-	9982
NF200-positive axons	9982
red , arrowheads	10004
red	10004
arrowheads	10009
the periphery of the lesion	10024
the periphery	10024
the lesion	10041
-LRB- F -RRB- Longitudinal section of the spinal cord lesion from a hOEC transplanted rat immunoreacted with ED1 to identify macrophages/microglia .	10053
-LRB- F -RRB- Longitudinal section of the spinal cord lesion from a hOEC	10053
-LRB- F -RRB- Longitudinal section	10053
F	10054
the spinal cord lesion from a hOEC	10081
the spinal cord lesion	10081
a hOEC	10109
transplanted rat immunoreacted with ED1 to identify macrophages/microglia	10116
transplanted rat	10116
ED1	10152
macrophages/microglia	10168
-LRB- G -RRB- High power image from -LRB- F -RRB- showing ED1-positive cells -LRB- red -RRB- co-localising with autofluorescent cells -LRB- yellow -RRB- within the lesion centre -LRB- open arrows -RRB- and ED1-positive macrophages/microglia that do not display autofluorescence in the white matter -LRB- closed arrows -RRB- .	10191
-LRB- G -RRB- High power	10191
G	10192
image from -LRB- F -RRB- showing ED1-positive cells -LRB- red -RRB- co-localising with autofluorescent cells -LRB- yellow -RRB- within the lesion centre -LRB- open arrows -RRB- and ED1-positive macrophages/microglia that do not display autofluorescence in the white matter -LRB- closed arrows -RRB-	10206
image	10206
F	10218
ED1-positive cells -LRB- red -RRB- co-localising with autofluorescent cells -LRB- yellow -RRB- within the lesion centre -LRB- open arrows -RRB- and ED1-positive macrophages/microglia that do not display autofluorescence in the white matter -LRB- closed arrows -RRB-	10229
ED1-positive cells -LRB- red -RRB-	10229
ED1-positive cells	10229
autofluorescent cells -LRB- yellow -RRB- within the lesion centre -LRB- open arrows -RRB- and ED1-positive macrophages/microglia that do not display autofluorescence in the white matter	10273
autofluorescent cells -LRB- yellow -RRB- within the lesion centre -LRB- open arrows -RRB-	10273
autofluorescent cells -LRB- yellow -RRB-	10273
autofluorescent cells	10273
the lesion centre -LRB- open arrows -RRB-	10311
the lesion centre	10311
open arrows	10330
ED1-positive macrophages/microglia that do not display autofluorescence in the white matter	10347
ED1-positive macrophages/microglia	10347
autofluorescence	10402
the white matter	10422
closed arrows	10440
2.1	10457
Twenty animals -LRB- 9 receiving hOECs and 11 controls -RRB-	10469
Twenty animals	10469
9 receiving hOECs and 11 controls	10485
9	10485
hOECs and 11 controls	10497
hOECs	10497
11 controls	10507
the final analysis	10533
Three animals	10553
the study	10586
the compression rate during spinal cord contusion and/or the initial BBB score	10604
the compression rate	10604
spinal cord contusion and/or the initial BBB score	10632
spinal cord contusion	10632
the initial BBB score	10661
more than two standard deviations from the group mean	10687
more than two standard deviations	10687
the group mean	10726
one animal	10745
post-operative complications	10776
The mean compression rate for the hOEC transplanted group was 0.36 ± 0.02 m/s compared to 0.38 ± 0.04 m/s for the control group .	10806
The mean compression rate for the hOEC	10806
The mean compression rate	10806
the hOEC	10836
transplanted group	10845
0.36 ± 0.02 m/s compared to 0.38 ± 0.04 m/s for the control group	10868
0.36 ± 0.02 m/s	10868
0.38 ± 0.04 m/s for the control group	10895
0.38 ± 0.04 m/s	10895
the control group	10913
There	10932
no difference between the groups -LRB- t = 0.658 , df 18 , p = 0.52 -RRB-	10942
no difference	10942
the groups -LRB- t = 0.658 , df 18 , p = 0.52 -RRB-	10964
the groups	10964
t = 0.658 , df 18 , p = 0.52	10976
t = 0.658	10976
t	10976
0.658	10978
df 18	10985
df	10985
18	10988
p = 0.52	10992
p	10992
0.52	10994
The lesion locations	11001
the transplanted and non-transplanted group lesions	11042
The positioning of the impactor head between the T9 and T11 vertebrate preventsmuch variation in lesion location between animals .	11095
The positioning of the impactor head between the T9 and T11 vertebrate	11095
The positioning	11095
the impactor head between the T9 and T11 vertebrate	11114
the impactor head	11114
the T9 and T11 vertebrate	11140
preventsmuch variation in lesion location between animals	11166
preventsmuch variation	11166
lesion location between animals	11192
lesion location	11192
animals	11216
There	11225
a small decrease in body weight -LRB- < 10 % -RRB- in the first week	11235
a small decrease	11235
body weight -LRB- < 10 % -RRB- in the first week	11255
body weight -LRB- < 10 % -RRB-	11255
body weight	11255
< 10 %	11268
<	11268
10 %	11269
the first week	11277
the surgery that then increased during the 6-week post-contusion period to above baseline levels	11298
the surgery	11298
the 6-week post-contusion period	11337
baseline levels	11379
All rats	11396
urine	11432
2 weeks post-contusion surgery	11441
2 weeks	11441
The cell transplantation procedure 1 week after spinal cord contusion	11473
The cell transplantation procedure	11473
1 week	11508
spinal cord contusion	11521
any noticeable adverse effects	11557
obvious locomotor deficits	11597
all animals	11625
surgery	11674
2.2	11683
Phenotyping of cells	11688
Phenotyping	11688
cells	11703
transduction with pFB-hrGFP	11718
transduction	11718
pFB-hrGFP	11736
cells	11747
antibodies against glial fibrillary acidic protein -LRB- GFAP ; Dako , Denmark -RRB- , S100 -LRB- Dako , Denmark -RRB- , p75NTR -LRB- Neubody , AUS -RRB- and R-phycoerythrin-conjugated anti- HNK1 -LRB- Sigma -RRB-	11795
antibodies	11795
glial fibrillary acidic protein -LRB- GFAP ; Dako , Denmark -RRB- , S100 -LRB- Dako , Denmark -RRB- , p75NTR -LRB- Neubody , AUS -RRB- and R-phycoerythrin-conjugated anti- HNK1 -LRB- Sigma -RRB-	11814
glial fibrillary acidic protein -LRB- GFAP ; Dako , Denmark -RRB-	11814
glial fibrillary acidic protein	11814
GFAP ; Dako , Denmark	11847
GFAP	11847
Dako , Denmark	11853
S100 -LRB- Dako , Denmark -RRB-	11869
S100	11869
Dako	11875
Denmark	11881
p75NTR -LRB- Neubody , AUS -RRB-	11891
p75NTR	11891
Neubody	11899
AUS	11908
R-phycoerythrin-conjugated anti- HNK1 -LRB- Sigma -RRB-	11917
R-phycoerythrin-conjugated anti- HNK1	11917
Sigma	11956
The percentages of S100-positive and GFAP positive cells	11964
The percentages	11964
S100-positive and GFAP positive cells	11983
GFAP	12001
95 % , nearly all cells	12027
95 %	12027
nearly all cells	12032
p75 NTR immunoreactive	12059
p75 NTR	12059
there	12086
no staining of NHK 1 antibody -LRB- Feron et al. , 2005 -RRB- indicating the culture was highly enriched for OEC	12096
no staining	12096
NHK	12111
1 antibody -LRB- Feron et al. , 2005 -RRB- indicating the culture	12115
1 antibody -LRB- Feron et al. , 2005 -RRB-	12115
Feron	12127
et al. , 2005	12133
et al.	12133
2005	12141
the culture	12158
OEC	12194
immunophenotyping of these cells	12207
immunophenotyping	12207
these cells	12228
transplantation	12254
no expression of any of these markers	12277
no expression	12277
any of these markers	12294
any	12294
these markers	12301
reasons	12320
Discussion	12341
we	12353
the most likely explanation for this loss of expression is due to plasticity of the OECs which is well known to occur in vitro -LRB- Barnett et al. , 2000 ; Vincent et al. , 2003 , 2005 ; Moreno-Flores et al. , 2003 -RRB- , rather than replacement of all the OECs by another immunonegative cell type	12365
the most likely explanation	12365
this loss of expression is due to plasticity of the OECs which is well known to occur in vitro -LRB- Barnett et al. , 2000 ; Vincent et al. , 2003 , 2005 ; Moreno-Flores et al. , 2003 -RRB- , rather than replacement of all the OECs by another immunonegative cell type	12397
this loss of expression	12397
this loss	12397
expression	12410
plasticity of the OECs which is well known to occur in vitro -LRB- Barnett et al. , 2000 ; Vincent et al. , 2003 , 2005 ; Moreno-Flores et al. , 2003 -RRB-	12431
plasticity	12431
the OECs which is well known to occur in vitro -LRB- Barnett et al. , 2000 ; Vincent et al. , 2003 , 2005 ; Moreno-Flores et al. , 2003 -RRB-	12445
the OECs	12445
Barnett et al. , 2000 ; Vincent et al. , 2003 , 2005 ; Moreno-Flores et al. , 2003	12493
Barnett et al.	12493
Barnett	12493
et al.	12501
2000 ; Vincent et al.	12509
2000	12509
Vincent et al.	12515
Vincent	12515
et al.	12523
2003	12531
2005 ; Moreno-Flores et al. , 2003	12537
2005	12537
Moreno-Flores et al. , 2003	12543
Moreno-Flores	12543
et al. , 2003	12557
et al.	12557
2003	12565
replacement of all the OECs by another immunonegative cell type	12584
replacement	12584
all the OECs by another immunonegative cell type	12599
all the OECs	12599
another immunonegative cell type	12615
We	12649
the term hOECs	12672
these transplants	12699
their identity	12734
2.3	12765
Behavioural assessments 2.3.1 .	12770
Behavioural assessments	12770
2.3.1	12794
field assessment	12806
the 6 weeks following hOEC transplantation or medium injection	12830
the 6 weeks	12830
hOEC transplantation or medium injection	12852
hOEC transplantation	12852
medium injection	12876
there	12893
an increase in BBB scores for both groups -LRB- Fig. 1A -RRB- with a significantly greater improvement in the hOEC transplant group , -LRB- two way ANOVA repeated measures , F -LRB- 1,18 -RRB- = 9.6 , p = 0.006 -RRB-	12903
an increase	12903
BBB scores for both groups -LRB- Fig. 1A -RRB- with a significantly greater improvement in the hOEC transplant group	12918
BBB scores	12918
both groups -LRB- Fig. 1A -RRB- with a significantly greater improvement in the hOEC transplant group	12933
both groups -LRB- Fig. 1A -RRB-	12933
both groups	12933
Fig. 1A	12946
a significantly greater improvement in the hOEC transplant group	12960
a significantly greater improvement	12960
the hOEC transplant group	12999
two way ANOVA repeated measures , F -LRB- 1,18 -RRB- = 9.6 , p = 0.006	13027
two way	13027
ANOVA	13035
measures , F -LRB- 1,18 -RRB- = 9.6 ,	13050
measures	13050
F -LRB- 1,18 -RRB- = 9.6	13060
F -LRB- 1,18 -RRB-	13060
F	13060
1,18	13063
9.6	13069
p = 0.006	13074
p	13074
0.006	13076
Bonferroni	13084
hoc tests show significant increases in the OEC group by 4 weeks post injury	13100
hoc	13100
tests	13104
significant increases in the OEC group	13115
significant increases	13115
the OEC group	13140
4 weeks post injury	13157
4 weeks	13157
The BBB scores obtained by the hOEC transplanted animals at 6 weeks -LRB- 15.8 ± 2.9 -RRB-	13178
The BBB scores	13178
the hOEC transplanted animals at 6 weeks	13205
the hOEC transplanted animals	13205
6 weeks	13238
15.8 ± 2.9	13247
15.8 ±	13247
2.9	13252
better hind-fore limb coordination , paw placement and trunk stability	13266
better hind-fore limb coordination	13266
paw placement	13302
trunk stability	13320
the controls -LRB- 12.45 ± 2.0 -RRB-	13348
the controls	13348
12.45 ± 2.0	13362
12.45 ±	13362
2.0	13368
2.3.2	13374
Horizontal Ladder	13381
test	13412
Six weeks	13417
transplantation	13433
most animals	13449
withweight support andmostwere	13484
the horizontal ladder	13535
the animals	13569
this task	13601
the hindlimb deficits	13615
the open field test	13670
Each animal	13691
variability	13710
the task	13736
spasms or jumps	13766
movement	13785
a stepping error	13812
Only consecutive steps completed after the rat	13830
Only consecutive steps	13830
the rat	13869
itself	13892
The hOEC-treated group	13912
significantly fewer stepping errors	13940
this task -LRB- 34.2 ± 20 % -RRB- than the control group -LRB- 50.8 ± 15.5 % -RRB- , -LRB- t = 2.12 , df 15 , p = 0.05 -RRB- -LRB- Fig. 1B -RRB-	13979
this task -LRB- 34.2 ± 20 % -RRB-	13979
this task	13979
34.2 ± 20 %	13990
34.2	13990
20 %	13995
the control group -LRB- 50.8 ± 15.5 % -RRB- , -LRB- t = 2.12 , df 15 , p = 0.05 -RRB- -LRB- Fig. 1B -RRB-	14005
the control group -LRB- 50.8 ± 15.5 % -RRB- , -LRB- t = 2.12 , df 15 , p = 0.05 -RRB-	14005
the control group -LRB- 50.8 ± 15.5 % -RRB-	14005
the control group	14005
50.8 ± 15.5 %	14024
50.8	14024
15.5 %	14029
t = 2.12 , df 15 , p = 0.05	14038
t = 2.12	14038
t	14038
= 2.12	14039
df 15	14046
df	14046
15	14049
p = 0.05	14053
p	14053
0.05	14055
Fig. 1B	14062
2.4	14072
Histological analysis 2.4.1 .	14077
Histological analysis	14077
2.4.1	14099
Lesion size This moderate contusion	14106
Lesion size	14106
This moderate contusion	14118
a typical `` oval '' shaped injury with a large centrally located lesion containing necrotic tissue , cellular debris , macrophages , cystic cavities and trabeculae of tissue -LRB- Fig. 2A -- E -RRB-	14154
a typical `` oval '' shaped injury	14154
a large centrally located lesion containing necrotic tissue , cellular debris , macrophages , cystic cavities and trabeculae of tissue	14190
a large centrally located lesion	14190
necrotic tissue , cellular debris , macrophages , cystic cavities and trabeculae of tissue	14234
necrotic tissue	14234
cellular debris	14251
macrophages	14268
cystic cavities	14281
trabeculae of tissue	14301
trabeculae	14301
tissue	14315
Fig. 2A -- E	14323
Fig. 2A	14323
E	14331
the lesion	14347
there	14358
relative sparing of tissue but extensive diffuse axonal injury in the white matter	14368
relative sparing of tissue	14368
relative sparing	14368
tissue	14388
extensive diffuse axonal injury in the white matter	14399
extensive diffuse axonal injury	14399
the white matter	14434
The terminal bulbs of axons	14452
The terminal bulbs	14452
axons	14474
their smooth rounded appearance	14501
eosinophilic staining in H&E	14537
eosinophilic staining	14537
H&E	14562
sections -LRB- Fig. 2C -RRB-	14574
sections	14574
Fig. 2C	14584
the peripheral white matter with NF-200 staining -LRB- Fig. 5D -RRB-	14625
the peripheral white matter	14625
NF-200 staining -LRB- Fig. 5D -RRB-	14658
NF-200 staining	14658
Fig. 5D	14675
Spinal cords with hOEC transplants	14685
Spinal cords	14685
hOEC transplants	14703
smaller lesions with less cavitation -LRB- Fig. 2B , E -RRB-	14724
smaller lesions	14724
less cavitation -LRB- Fig. 2B , E -RRB-	14745
less cavitation	14745
Fig. 2B , E	14762
Fig. 2B	14762
E	14771
The overall percentage of lesion area	14775
The overall percentage	14775
lesion area	14801
the hOEC transplanted spinal cords -LRB- 37.2 ± 6.6 % -RRB- compared to the controls -LRB- 51.04 ± 5.4 % -RRB- , -LRB- t = 5.1 , df 18 , p < 0.001 -RRB-	14840
the hOEC	14840
spinal cords -LRB- 37.2 ± 6.6 % -RRB- compared to the controls -LRB- 51.04 ± 5.4 % -RRB- , -LRB- t = 5.1 , df 18 , p < 0.001 -RRB-	14862
spinal cords -LRB- 37.2 ± 6.6 % -RRB-	14862
spinal cords	14862
37.2 ± 6.6 %	14876
37.2	14876
6.6 %	14881
the controls -LRB- 51.04 ± 5.4 % -RRB- , -LRB- t = 5.1 , df 18 , p < 0.001 -RRB-	14899
controls -LRB- 51.04 ± 5.4 % -RRB- , -LRB- t = 5.1 , df 18 , p < 0.001 -RRB-	14903
controls -LRB- 51.04 ± 5.4 % -RRB-	14903
controls	14903
51.04 ± 5.4 %	14913
51.04	14913
5.4 %	14919
t = 5.1 , df 18 , p < 0.001	14927
t = 5.1	14927
t	14927
df 18	14934
df	14934
18	14937
p < 0.001	14941
p <	14941
p	14941
0.001	14943
The dorsal part of the cord	14951
The dorsal part	14951
the cord	14970
the most injury	14989
there	15009
no difference in severity for hOEC transplanted animals and controls at this level	15019
no difference	15019
severity for hOEC transplanted animals and controls at this level	15036
severity for hOEC transplanted animals	15036
severity	15036
hOEC transplanted animals	15049
controls at this level	15079
controls	15079
this level	15091
each of the middle levels through the cord the hOEC	15106
each	15106
the middle levels through the cord the hOEC	15114
the middle levels	15114
the cord the hOEC	15140
the cord	15140
the hOEC	15149
transplanted animals	15158
consistently smaller lesion sizes -LRB- Fig. 3A -RRB-	15186
consistently smaller lesion sizes	15186
Fig. 3A	15221
the lesion	15238
the overall percentage of cavity area	15250
the overall percentage	15250
cavity area	15276
hOEC groups -LRB- 3.1 ± 2.7 % -RRB- compared to the controls -LRB- 15.5 ± 15.3 % -RRB- , -LRB- t = 2.2 , df 18 , p = 0.038 -RRB-	15318
hOEC groups -LRB- 3.1 ± 2.7 % -RRB-	15318
hOEC groups	15318
3.1 ± 2.7 %	15331
3.1	15331
2.7 %	15336
the controls -LRB- 15.5 ± 15.3 % -RRB- , -LRB- t = 2.2 , df 18 , p = 0.038 -RRB-	15354
controls -LRB- 15.5 ± 15.3 % -RRB- , -LRB- t = 2.2 , df 18 , p = 0.038 -RRB-	15358
controls -LRB- 15.5 ± 15.3 % -RRB-	15358
controls	15358
15.5 ± 15.3 %	15368
15.5	15368
15.3 %	15373
t = 2.2 , df 18 , p = 0.038	15382
t = 2.2	15382
t	15382
2.2	15384
df 18	15389
df	15389
18	15392
p = 0.038	15396
p	15396
0.038	15398
Cavitation	15406
highest in the middle sections of the spinal cord for both groups	15421
highest	15421
the middle sections of the spinal cord for both groups	15432
the middle sections	15432
the spinal cord for both groups	15455
the spinal cord	15455
both groups	15475
the controls showing significantly greater cavitation than hOEC transplanted animals at the central level -LRB- Fig. 3B -RRB-	15493
the controls	15493
significantly greater cavitation	15514
hOEC transplanted animals at the central level -LRB- Fig. 3B -RRB-	15552
hOEC transplanted animals	15552
the central level -LRB- Fig. 3B -RRB-	15581
the central level	15581
Fig. 3B	15600
The highest percentage of spared tissue	15610
The highest percentage	15610
spared tissue	15636
the ventral part of the spinal cord for both groups	15666
the ventral part	15666
the spinal cord for both groups	15686
the spinal cord	15686
both groups	15706
there	15735
differential sparing in the hOEC-transplanted animals -LRB- 35 ± 6.24 % -RRB- compared to the controls -LRB- 25.9 ± 1.1 % -RRB- , -LRB- t = -2.1 , df 18 , p = 0.054 -RRB- , most apparent in the central and ventral parts of the cord -LRB- Fig. 3C -RRB-	15745
differential sparing	15745
the hOEC-transplanted animals -LRB- 35 ± 6.24 % -RRB- compared to the controls -LRB- 25.9 ± 1.1 % -RRB- , -LRB- t = -2.1 , df 18 , p = 0.054 -RRB- , most apparent in the central and ventral parts of the cord -LRB- Fig. 3C -RRB-	15769
the hOEC-transplanted animals -LRB- 35 ± 6.24 % -RRB-	15769
the hOEC-transplanted animals	15769
35 ± 6.24 %	15800
35	15800
6.24 %	15803
the controls -LRB- 25.9 ± 1.1 % -RRB- , -LRB- t = -2.1 , df 18 , p = 0.054 -RRB- , most apparent	15822
the controls -LRB- 25.9 ± 1.1 % -RRB- , -LRB- t = -2.1 , df 18 , p = 0.054 -RRB-	15822
the controls -LRB- 25.9 ± 1.1 % -RRB-	15822
the controls	15822
25.9 ± 1.1 %	15836
25.9	15836
1.1 %	15841
t = -2.1 , df 18 , p = 0.054	15850
t = -2.1	15850
t	15850
-2.1	15852
df 18	15858
df	15858
18	15861
p = 0.054	15865
p	15865
0.054	15867
the central and ventral parts of the cord -LRB- Fig. 3C -RRB-	15892
the central and ventral parts	15892
the cord -LRB- Fig. 3C -RRB-	15925
the cord	15925
Fig. 3C	15935
2.4.2	15945
hOEC survival	15952
Six weeks	15966
transplantation into the lesion site	15982
transplantation	15982
the lesion site	16003
the hOECs	16019
the lesion -LRB- Fig. 4A -RRB- , aligned in a rostro-caudal direction -LRB- Fig. 4B -RRB- and clustered at the periphery of the lesion both at the lateral white matter border and near the rostral and caudal grey matter	16057
the lesion -LRB- Fig. 4A -RRB-	16057
the lesion	16057
Fig. 4A	16069
a rostro-caudal direction -LRB- Fig. 4B -RRB-	16090
a rostro-caudal direction	16090
Fig. 4B	16117
the periphery of the lesion	16143
the periphery	16143
the lesion	16160
the lateral white matter border	16179
the rostral and caudal grey matter	16220
the rostral	16220
caudal grey matter	16236
a few individual cells -LRB- Fig. 4C -RRB-	16267
a few individual cells	16267
Fig. 4C	16291
hOECs	16300
the lesion	16327
spinal cord tissue	16355
2.4.3	16375
Immunohistochemistry Six weeks after transplantation , GFAP staining intensity	16382
Immunohistochemistry	16382
Six weeks	16403
transplantation , GFAP staining intensity	16419
transplantation	16419
GFAP staining intensity	16436
the lesion in controls -LRB- Fig. 5A -RRB-	16498
the lesion	16498
controls -LRB- Fig. 5A -RRB-	16512
controls	16512
Fig. 5A	16522
a lesser extent in hOEC	16538
a lesser extent	16538
hOEC	16557
transplanted spinal cords -LRB- Fig. 5B -RRB-	16562
transplanted spinal cords	16562
Fig. 5B	16589
Quantification of the GFAP staining intensity	16599
Quantification	16599
the GFAP staining intensity	16617
an overall 17 % reduction	16652
GFAP intensity in hOEC transplanted rats	16680
GFAP intensity	16680
hOEC transplanted rats	16698
The control animals	16722
a 27	16749
9.5 %	16754
increase in GFAP staining intensity adjacent to the lesion compared to an increase of 10 ± 6.6 % in the hOEC transplanted animals -LRB- t = 4.5 , df 18 , p = 0.001 -RRB-	16759
increase	16759
GFAP staining intensity adjacent to the lesion compared to an increase of 10 ± 6.6 % in the hOEC transplanted animals	16771
GFAP staining intensity	16771
the lesion compared to an increase of 10 ± 6.6 % in the hOEC transplanted animals	16807
the lesion	16807
an increase of 10 ± 6.6 % in the hOEC transplanted animals	16830
an increase	16830
10 ± 6.6 % in the hOEC transplanted animals	16845
the hOEC	16857
t = 4.5 , df 18 , p = 0.001	16888
t = 4.5	16888
t	16888
4.5	16890
df 18	16895
df	16895
18	16898
p = 0.001	16902
p	16902
0.001	16904
This pattern	16912
the spinal cord	16951
the ventral section	16980
significant differences -LRB- Fig. 3D -RRB-	17007
significant differences	17007
Fig. 3D	17032
High power examination at the edge of the lesion	17042
High power examination	17042
the edge of the lesion	17068
the edge	17068
the lesion	17080
close association	17098
some hOECs and GFAP positive astrocytes	17124
some hOECs	17124
GFAP positive astrocytes	17139
the host-graft interface -LRB- Fig. 5C -RRB-	17167
the host-graft interface	17167
Fig. 5C	17193
Occasional single hOECs	17203
short distances	17247
the white matter	17271
astrocytic processes	17293
the centre of the lesion	17342
the centre	17342
the lesion	17356
GFAP staining	17368
trabeculae of tissue fragments	17399
trabeculae	17399
tissue fragments	17413
the lesion centre	17437
NF200 staining	17456
large axons and terminal bulbs	17482
large axons	17482
the white matter adjacent to the lesion -LRB- Fig. 5D -RRB-	17516
the white matter	17516
the lesion -LRB- Fig. 5D -RRB-	17545
the lesion	17545
Fig. 5D	17557
hOECs	17567
close proximity	17589
axons at the caudal and rostral ends of the lesion	17608
axons	17608
the caudal and rostral ends of the lesion	17617
the caudal and rostral ends	17617
the lesion	17648
few of these axons	17663
few	17663
these axons	17670
the epicentre	17697
The hOECs	17712
the same direction as axons	17748
the same direction	17748
axons	17770
confocal examination	17780
a close association between some hOECs and NF200-positive axons -LRB- Fig. 5E -RRB-	17811
a close association	17811
some hOECs and NF200-positive axons -LRB- Fig. 5E -RRB-	17839
some hOECs and NF200-positive axons	17839
hOECs	17844
Fig. 5E	17876
it	17889
hOECs	17925
axons	17947
High numbers of large autofluorescent cells with macrophage morphology	17954
High numbers	17954
large autofluorescent cells with macrophage morphology	17970
large autofluorescent cells	17970
macrophage morphology	18003
the lesion centre of hOEC	18041
the lesion centre	18041
hOEC	18062
transplanted -LRB- Fig. 4A , D -- F -RRB- and control spinal cords	18067
transplanted -LRB- Fig. 4A , D -- F -RRB- and control	18067
transplanted -LRB- Fig. 4A , D -- F -RRB-	18067
transplanted	18067
Fig. 4A , D -- F	18081
Fig. 4A	18081
D -- F	18090
D	18090
F	18092
control	18099
spinal cords	18107
ED1	18135
a specific marker for rat myeloid cells	18140
a specific marker	18140
rat myeloid cells	18162
these	18191
macrophages or microglia -LRB- Fig. 5F , G -RRB-	18202
macrophages or microglia	18202
Fig. 5F , G	18228
Fig. 5F	18228
G	18237
there	18257
an extensive infiltration of ED1-positive cells in the white matter throughout the spinal cord segment	18272
an extensive infiltration	18272
ED1-positive cells in the white matter throughout the spinal cord segment	18301
ED1-positive cells	18301
the white matter throughout the spinal cord segment	18323
the white matter	18323
the spinal cord segment	18351
There	18376
no apparent difference in the amount or pattern of macrophage staining between hOEC transplanted and control spinal cords	18386
no apparent difference	18386
the amount or pattern of macrophage staining between hOEC transplanted and control spinal cords	18412
the amount or pattern	18412
macrophage staining between hOEC transplanted and control spinal cords	18437
macrophage staining	18437
hOEC transplanted and control spinal cords	18465
hOEC	18465
transplanted and control spinal cords	18470
transplanted	18470
control spinal cords	18487
Discussion	18513
this study	18527
we	18538
hOEC-derived cells from the olfactory mucosa	18551
hOEC-derived cells	18551
the olfactory mucosa	18575
significant locomotor and histological improvements	18604
transplantation	18662
the contused spinal cord of the rat	18683
the	18683
spinal cord of the rat	18696
spinal cord	18696
the rat	18711
controls	18732
the hOEC transplanted animals had significantly better hindlimb locomotor function in the open field test , fewer stepping errors in the horizontal ladder task ,	18741
the hOEC	18741
transplanted animals	18750
better hindlimb locomotor function in the open field test , fewer stepping errors in the horizontal ladder task ,	18789
better hindlimb locomotor function	18789
the open field test , fewer stepping errors in the horizontal ladder task ,	18827
the open field test	18827
fewer stepping errors in the horizontal ladder task	18848
fewer stepping errors	18848
the horizontal ladder task	18873
spinal cord	18909
lesion volume	18921
cavitation	18947
the lesion	18965
There	18977
evidence for reduced astrogliosis at the lesion site	18992
evidence	18992
reduced astrogliosis at the lesion site	19005
reduced astrogliosis	19005
the lesion site	19029
3.1	19046
Human OECs from olfactory mucosa The cells used in this study	19051
Human OECs	19051
olfactory mucosa The cells used in this study	19067
olfactory mucosa	19067
The cells	19084
this study	19102
the human olfactory mucosa	19130
OEC cultures from this source	19158
OEC cultures	19158
this source	19176
Schwann cells associated with the trigeminal nerve whose branches innervate olfactory epithelium and olfactory bulb -LRB- Schaefer et al. , 2002 -RRB- , or other cell types located in the olfactory mucosa , including precursor cells and stem cells -LRB- Lindsay et al. , 2010 -RRB-	19220
Schwann cells	19220
the trigeminal nerve whose branches innervate olfactory epithelium and olfactory bulb -LRB- Schaefer et al. , 2002 -RRB- , or other cell types located in the olfactory mucosa , including precursor cells and stem cells -LRB- Lindsay et al. , 2010 -RRB-	19250
the trigeminal nerve	19250
branches	19277
olfactory epithelium and olfactory bulb -LRB- Schaefer et al. , 2002 -RRB- , or other cell types located in the olfactory mucosa	19296
olfactory epithelium and olfactory bulb -LRB- Schaefer et al. , 2002 -RRB-	19296
olfactory epithelium and olfactory bulb	19296
Schaefer	19337
et al. , 2002	19346
et al.	19346
2002	19354
other cell types located in the olfactory mucosa	19364
other cell types	19364
the olfactory mucosa	19392
precursor cells and stem cells	19424
precursor cells	19424
stem cells	19444
Lindsay	19456
et al. , 2010	19464
et al.	19464
2010	19472
A comprehensive review article by Kawaja et al. -LRB- 2009 -RRB-	19479
A comprehensive review article by Kawaja et al.	19479
A comprehensive review article by Kawaja	19479
A comprehensive review article	19479
Kawaja	19513
et al.	19520
2009	19528
the technical challenges	19544
OECs	19609
olfactory bulb and mucosal tissue cultures	19619
Several antigenic markers , including calponin and smooth muscle actin ,	19663
Several antigenic markers	19663
calponin and smooth muscle actin	19700
calponin	19700
muscle actin	19720
OECs but not Schwann cells -LRB- Boyd et al. , 2006 ; Jahed et al. , 2007 -RRB-	19765
OECs	19765
Schwann cells -LRB- Boyd et al. , 2006 ; Jahed et al. , 2007 -RRB-	19778
Schwann cells	19778
Boyd	19793
et al. , 2006 ; Jahed et al. , 2007	19798
et al.	19798
2006 ; Jahed et al.	19806
2006	19806
Jahed et al.	19812
Jahed	19812
et al.	19818
2007	19826
these	19836
there	19894
no method to unequivocally distinguish between OECs and Schwann cells in vitro	19903
OECs and Schwann cells	19950
We	19983
a serum-free medium containing NT3 to selectively propagate OECs -LRB- Bianco et al. , 2004 -RRB-	19991
a serum-free medium	19991
NT3	20022
OECs -LRB- Bianco et al. , 2004 -RRB-	20051
OECs	20051
Bianco	20057
et al. , 2004	20064
et al.	20064
2004	20072
This medium	20079
long-term culture of Schwann cells -LRB- Cheng et al. , 1998 -RRB-	20108
long-term culture	20108
Schwann cells -LRB- Cheng et al. , 1998 -RRB-	20129
Schwann cells	20129
Cheng	20144
et al. , 1998	20150
et al.	20150
1998	20158
NT3	20173
survival of 50 % Schwann cells	20186
survival	20186
50 % Schwann cells	20198
the first 3 h of culture -LRB- Meier et al. , 1999 -RRB- and 20-30 % in the first 24 h -LRB- Lobsiger et al. , 2000 -RRB-	20219
the first 3 h of culture -LRB- Meier et al. , 1999 -RRB-	20219
the first 3 h	20219
culture -LRB- Meier et al. , 1999 -RRB-	20236
culture	20236
Meier	20245
et al. , 1999	20251
et al.	20251
1999	20259
20-30 % in the first 24 h -LRB- Lobsiger et al. , 2000 -RRB-	20269
20-30 %	20269
the first 24 h -LRB- Lobsiger et al. , 2000 -RRB-	20279
the first 24 h	20279
Lobsiger	20295
et al. , 2000	20304
et al.	20304
2000	20312
no cells	20332
HNK 1 , a marker that recognises human myelinating Schwann cells -LRB- Levi et al. , 1994 -RRB-	20362
HNK 1	20362
a marker that recognises human myelinating Schwann cells -LRB- Levi et al. , 1994 -RRB-	20369
a marker	20369
human myelinating Schwann cells -LRB- Levi et al. , 1994 -RRB-	20394
human myelinating Schwann cells	20394
Levi	20427
et al. , 1994	20432
et al.	20432
1994	20440
our paper	20458
we	20468
the transplanted cells as hOECs	20488
the transplanted cells	20488
hOECs	20514
we	20530
these cell preparations	20542
OECs	20592
it	20597
the transplants	20617
other , as yet unidentified , cell types from the olfactory mucosa	20641
other , as yet unidentified , cell types	20641
the olfactory mucosa	20685
The loss of expression of GFAP , S100 and P75 in these cells during their preparation -LRB- EGFP labelling , frozen storage and subsequent revival and expansion -RRB-	20707
The loss of expression of GFAP , S100 and P75 in these cells during their preparation	20707
The loss	20707
expression of GFAP , S100 and P75	20719
expression	20719
GFAP , S100 and P75	20733
these cells during their preparation	20755
these cells	20755
their preparation	20774
EGFP labelling , frozen storage and subsequent revival and expansion	20793
EGFP labelling	20793
frozen storage	20809
subsequent revival and expansion	20828
a matter of concern and one that will be further investigated by phenotyping cells at each step of their preparation using a more comprehensive panel of antibodies -LRB- Lim et al. , 2010 ; Garcia-Escudero , et al. , 2010 -RRB-	20865
a matter of concern	20865
a matter	20865
concern	20877
one that will be further investigated by phenotyping cells at each step of their preparation using a more comprehensive panel of antibodies -LRB- Lim et al. , 2010 ; Garcia-Escudero , et al. , 2010 -RRB-	20889
one	20889
phenotyping cells	20930
each step of their preparation	20951
each step	20951
their preparation	20964
a more comprehensive panel of antibodies -LRB- Lim et al. , 2010 ; Garcia-Escudero , et al. , 2010 -RRB-	20988
a more comprehensive panel	20988
antibodies -LRB- Lim et al. , 2010 ; Garcia-Escudero , et al. , 2010 -RRB-	21018
antibodies	21018
Lim	21030
et al. , 2010 ; Garcia-Escudero , et al. , 2010	21034
et al.	21034
2010 ; Garcia-Escudero , et al.	21042
2010	21042
Garcia-Escudero , et al.	21048
Garcia-Escudero	21048
et al.	21065
2010	21073
hOECs	21092
the same NT3 culture conditions	21110
the subsequent labelling and storage	21155
steps	21192
their GFAP	21209
+	21219
S100	21222
+	21226
p75-NGF + phenotype -LRB- Feron et al. , 2005 -RRB-	21229
p75-NGF + phenotype	21229
p75-NGF	21229
phenotype	21237
Feron	21248
et al. , 2005	21254
et al.	21254
2005	21262
OECs	21269
the expression of markers	21304
the expression	21304
markers	21322
culture conditions -LRB- Barnett et al. , 2000 ; Vincent et al. , 2003 , 2005 -RRB- and species -LRB- Bock et al. , 2007 ; Smithson and Kawaja , 2009 -RRB-	21342
culture conditions	21342
Barnett et al. , 2000 ; Vincent et al. , 2003 , 2005	21362
Barnett et al.	21362
Barnett	21362
et al.	21370
2000 ; Vincent et al.	21378
2000	21378
Vincent et al.	21384
Vincent	21384
et al.	21392
2003 , 2005	21400
2003	21400
2005	21406
species	21416
Bock	21425
et al. , 2007 ; Smithson and Kawaja , 2009	21430
et al.	21430
2007 ; Smithson and Kawaja	21438
2007	21438
Smithson and Kawaja	21444
2009	21465
p75-NGF	21472
incubation in 10 % fetal calf serum	21505
incubation	21505
10 % fetal calf serum	21519
loss of regenerative capacity -LRB- Moreno-Flores et al. , 2003 -RRB-	21548
loss	21548
regenerative capacity	21556
Moreno-Flores	21579
et al. , 2003	21593
et al.	21593
2003	21601
It	21608
the hOECs	21628
their immunological phenotype	21648
the particular protocol we used	21685
the particular protocol	21685
we	21709
The less likely possibility	21718
OECs -LRB- and Schwann cells -RRB-	21763
OECs	21763
Schwann cells	21773
the cell culture	21815
transplantation	21853
it	21874
a different cell population	21900
A recent review -LRB- Lindsay et al. , 2010 -RRB-	21929
A recent review	21929
Lindsay	21946
et al. , 2010	21954
et al.	21954
2010	21962
the complexity and heterogenicity of cells located in the human olfactory mucosa	21977
the complexity and heterogenicity	21977
cells located in the human olfactory mucosa	22014
cells	22014
the human olfactory mucosa	22031
this	22062
the case	22070
it	22084
these cells	22111
we	22126
their potential	22147
function	22177
spinal cord injury	22192
Clinical application of OECs	22212
Clinical application	22212
OECs	22236
an accessible source of these cells	22250
an accessible source	22250
these cells	22274
the majority of experiments	22290
the majority	22290
experiments	22306
OECs	22318
the rodent olfactory bulb	22342
amethod	22372
unilateral bulbectomy	22401
the frontal bone in primate -LRB- Rubio et al. , 2008 -RRB-	22431
the frontal bone	22431
primate -LRB- Rubio et al. , 2008 -RRB-	22451
primate	22451
Rubio	22460
et al. , 2008	22466
et al.	22466
2008	22474
OECs	22481
postmortem brain -LRB- Barnett et al. , 2000 -RRB-	22510
postmortem brain	22510
Barnett	22528
et al. , 2000	22536
et al.	22536
2000	22544
a clinically preferable source	22554
the olfactory mucosa , accessible through the external naris -LRB- Feron et al. , 1998 ; Bianco et al. , 2004 -RRB- because there is little morbidity	22588
the olfactory mucosa	22588
the external naris -LRB- Feron et al. , 1998 ; Bianco et al. , 2004 -RRB- because there is little morbidity	22629
the external naris	22629
Feron	22649
et al. , 1998 ; Bianco et al. , 2004	22655
et al.	22655
1998 ; Bianco et al.	22663
1998	22663
Bianco et al.	22669
Bianco	22669
et al.	22676
2004	22684
there	22698
little morbidity	22707
it	22728
autologous transplantation -LRB- Feron et al. , 2005 ; Mackay-Sim et al. , 2008 -RRB-	22738
autologous transplantation	22738
Feron	22766
et al. , 2005 ; Mackay-Sim et al. , 2008	22772
et al.	22772
2005 ; Mackay-Sim et al.	22780
2005	22780
Mackay-Sim et al.	22786
Mackay-Sim	22786
et al.	22797
2008	22805
This	22812
the first study in which hOECs were transplanted into the contusion model of spinal cord injury	22820
the first study	22820
hOECs	22845
the contusion model of spinal cord injury	22874
the contusion model	22874
spinal cord injury	22897
the results	22920
more marked post-transplantation improvements in hindlimb locomotion	22937
more marked post-transplantation improvements	22937
hindlimb locomotion	22986
rodent OEC transplantation in similar models -LRB- Barakat et al. , 2005 ; Pearse et al. , 2004 ; Takami et al. , 2002 -RRB-	23018
rodent OEC transplantation	23018
similar models -LRB- Barakat et al. , 2005 ; Pearse et al. , 2004 ; Takami et al. , 2002 -RRB-	23048
similar models	23048
Barakat et al. , 2005 ; Pearse et al. , 2004 ; Takami et al. , 2002	23064
Barakat	23064
et al. , 2005 ; Pearse et al. , 2004 ; Takami et al. , 2002	23072
et al. , 2005	23072
et al.	23072
2005	23080
Pearse et al. , 2004	23086
Pearse	23086
et al. , 2004	23093
et al.	23093
2004	23101
Takami et al. , 2002	23107
Takami	23107
et al. , 2002	23114
et al.	23114
2002	23122
This	23129
the possibility	23141
hOECs	23162
rodent OECs	23197
recent in vitro studies of rodent , canine , primate and human OECs which show interspecies differences in proliferation and responses to growth factors -LRB- Barnett et al. , 2000 ; Krudewig et al. , 2006 ; Rubio et al. , 2008 -RRB-	23225
recent in vitro studies of rodent , canine , primate and human OECs which show interspecies differences in proliferation	23225
recent	23225
studies of rodent , canine , primate and human OECs which show interspecies differences in proliferation	23241
studies	23241
rodent , canine , primate and human OECs	23252
interspecies differences in proliferation	23302
interspecies differences	23302
proliferation	23330
responses to growth factors -LRB- Barnett et al. , 2000 ; Krudewig et al. , 2006 ; Rubio et al. , 2008 -RRB-	23348
responses	23348
growth factors -LRB- Barnett et al. , 2000 ; Krudewig et al. , 2006 ; Rubio et al. , 2008 -RRB-	23361
growth factors	23361
Barnett et al. , 2000 ; Krudewig et al. , 2006 ; Rubio et al. , 2008	23377
Barnett	23377
et al. , 2000 ; Krudewig et al. , 2006 ; Rubio et al. , 2008	23385
et al. , 2000	23385
et al.	23385
2000	23393
Krudewig et al. , 2006	23399
Krudewig	23399
et al. , 2006	23408
et al.	23408
2006	23416
Rubio et al. , 2008	23422
Rubio	23422
et al. , 2008	23428
et al.	23428
2008	23436
Another source of variation between studies	23443
Another source	23443
variation between studies	23461
variation	23461
studies	23479
the different methods of cell culture used in different laboratories	23496
the different methods	23496
cell culture used in different laboratories	23521
cell culture	23521
different laboratories	23542
There	23566
variability in the reported survival of OECs after transplantation into the spinal cord	23575
variability	23575
the reported survival of OECs after transplantation into the spinal cord	23590
the reported survival	23590
OECs after transplantation into the spinal cord	23615
OECs	23615
transplantation into the spinal cord	23626
transplantation	23626
the spinal cord	23647
The use of genetic reporter GFP	23664
The use	23664
genetic reporter GFP	23675
unequivocal visualisation	23705
transplantation -LRB- Guest et al. , 2008 ; Pearse et al. , 2007 ; Sasaki et al. , 2007 -RRB-	23737
transplantation	23737
Guest et al. , 2008 ; Pearse et al. , 2007 ; Sasaki et al. , 2007	23754
Guest	23754
et al. , 2008 ; Pearse et al. , 2007 ; Sasaki et al. , 2007	23760
et al. , 2008	23760
et al.	23760
2008	23768
Pearse et al. , 2007	23774
Pearse	23774
et al. , 2007	23781
et al.	23781
2007	23789
Sasaki et al. , 2007	23795
Sasaki	23795
et al. , 2007	23802
et al.	23802
2007	23810
hOECs	23820
6 weeks	23839
our study	23850
The timing of hOEC transplantation in this study	23861
The timing	23861
hOEC transplantation in this study	23875
hOEC transplantation	23875
this study	23899
7 days	23928
contusion injury	23941
this	23966
transplantation	24015
the time of injury	24034
the time	24034
injury	24046
Plant et al. , 2003	24054
Plant	24054
et al.	24060
2003	24068
The toxicity of the lesion site to transplanted OECs	24075
The toxicity	24075
the lesion site to transplanted OECs	24091
the lesion site	24091
transplanted OECs	24110
differences in the survival rate : 69 % at 3 days to less than 5 % by 3 -- 9 weeks after transplantation into the epicentre of a contusion lesion	24148
differences in the survival rate : 69 % at 3 days to less than 5 % by 3 -- 9 weeks after transplantation	24148
differences in the survival rate	24148
differences	24148
the survival rate	24163
69 % at 3 days to less than 5 % by 3	24182
69 %	24182
3 days to less than 5 % by 3	24189
3 days	24189
less than 5 % by 3	24199
less than 5 %	24199
3	24215
9 weeks after transplantation	24217
9 weeks	24217
transplantation	24231
the epicentre of a contusion lesion	24252
the epicentre	24252
a contusion lesion	24269
a 60 % survival rate when transplanted away from the lesion -LRB- Pearse et al. , 2007 -RRB-	24300
a 60 % survival rate	24300
the lesion -LRB- Pearse et al. , 2007 -RRB-	24348
the lesion	24348
Pearse	24360
et al. , 2007	24367
et al.	24367
2007	24375
In vitro experiments	24382
apoptosis of OECs	24428
apoptosis	24428
OECs	24441
acutely injured spinal cord explants	24496
delayed injury explants -LRB- Woodhouse et al. , 2005 -RRB-	24545
delayed injury explants	24545
Woodhouse	24570
et al. , 2005	24580
et al.	24580
2005	24588
3.2	24595
hOECs	24600
locomotor ability	24615
controls As expected , our results showed that the injury was most severe at the dorsal surface of the spinal cord where the impact occurred	24645
controls	24645
our results	24667
the injury	24691
the dorsal surface of the spinal cord	24721
the dorsal surface	24721
the spinal cord	24743
the impact	24765
Tissue	24786
deeper levels	24805
the spinal cord	24830
injury severity	24858
the impact site	24901
the most spared tissue located ventrally as described by Basso	24922
the most	24922
tissue	24938
Basso	24979
et al. -LRB- 1996 -RRB-	24985
et al.	24985
1996	24993
accordance with this	25003
accordance	25003
this	25019
most animals in our study	25025
most animals	25025
our study	25041
weight support	25065
stance	25083
some degree of weight	25093
some degree	25093
weight	25108
2 weeks	25137
injury and this improved over the following 4 weeks	25151
injury	25151
this improved over the following 4 weeks	25162
this	25162
the following 4 weeks	25181
their higher BBB scores	25220
hOEC transplanted animals	25245
hOEC	25245
animals	25263
more `` consistent '' hind-fore limb co-ordination compared to `` occasional '' or `` frequent '' for the control groups , and more parallel paw placement	25275
more `` consistent '' hind-fore	25275
limb co-ordination compared to `` occasional '' or `` frequent '' for the control groups , and more parallel paw placement	25303
limb co-ordination	25303
`` occasional '' or `` frequent '' for the control groups , and more parallel paw placement	25334
`` occasional '' or `` frequent '' for the control groups	25334
`` occasional '' or `` frequent ''	25334
the control groups	25365
more parallel paw placement	25389
a rotated placement for the controls	25430
a rotated placement	25430
the controls	25454
These differences in locomotor ability	25468
These differences	25468
locomotor ability	25489
the horizontal ladder task -LRB- Metz and Whishaw , 2002 -RRB- compared to the open field assessment -LRB- Basso et al. , 1995 -RRB-	25529
the horizontal ladder task -LRB- Metz and Whishaw , 2002 -RRB-	25529
the horizontal ladder task	25529
Metz and Whishaw , 2002	25557
Metz	25557
Whishaw , 2002	25566
Whishaw	25566
2002	25575
the open field assessment	25593
Basso	25620
et al. , 1995	25626
et al.	25626
1995	25634
there	25655
differential sparing of tissue for the hOEC transplanted animals compared to the controls particularly in the central to ventral parts of the cord	25665
differential sparing	25665
tissue for the hOEC transplanted animals compared to the controls particularly in the central to ventral parts of the cord	25689
tissue	25689
the hOEC transplanted animals compared to the controls particularly in the central to ventral parts of the cord	25700
the hOEC transplanted animals	25700
the controls particularly in the central to ventral parts of the cord	25742
the controls	25742
the central to ventral parts of the cord	25771
the central to ventral parts	25771
the cord	25803
the rat	25816
descending spinal tracts located in this region	25825
descending spinal tracts	25825
this region	25861
the medullary and pontine reticulospinal tracts , the medial and lateral vestibulospinal tracts and raphespinal fibres projecting from the raphe obscurus and pallidus nuclei -LRB- Watson et al. , 2009 -RRB-	25881
the medullary and pontine reticulospinal tracts , the medial and lateral vestibulospinal tracts and raphespinal fibres	25881
the medullary and pontine reticulospinal tracts	25881
the medial and lateral vestibulospinal tracts	25930
raphespinal fibres	25980
the raphe obscurus and pallidus nuclei -LRB- Watson et al. , 2009 -RRB-	26015
the raphe obscurus	26015
pallidus nuclei -LRB- Watson et al. , 2009 -RRB-	26038
pallidus nuclei	26038
Watson	26055
et al. , 2009	26062
et al.	26062
2009	26070
These tracts	26077
the maintenance of posture and balance	26106
the maintenance	26106
posture and balance	26125
walking and the initiation and maintenance of locomotion -LRB- Fouad and Pearson , 2004 -RRB-	26152
walking	26152
the initiation and maintenance of locomotion -LRB- Fouad and Pearson , 2004 -RRB-	26164
the initiation and maintenance	26164
locomotion -LRB- Fouad and Pearson , 2004 -RRB-	26198
locomotion	26198
Fouad and Pearson , 2004	26210
Fouad	26210
Pearson , 2004	26220
Pearson	26220
2004	26229
Plasticity or regeneration of these fibre tracts	26236
Plasticity or regeneration	26236
these fibre tracts	26266
functional hindlimb recovery following spinal lesions -LRB- Ballermann and Fouad , 2006 ; Ito et al. , 1999 ; Lopez-Vales et al. , 2007 ; Lu et al. , 2002 ; Boido et al. , 2009 -RRB-	26314
functional hindlimb recovery	26314
spinal lesions -LRB- Ballermann and Fouad , 2006 ; Ito et al. , 1999 ; Lopez-Vales et al. , 2007 ; Lu et al. , 2002 ; Boido et al. , 2009 -RRB-	26353
spinal lesions	26353
Ballermann and Fouad , 2006 ; Ito et al. , 1999 ; Lopez-Vales et al. , 2007 ; Lu et al. , 2002 ; Boido et al. , 2009	26369
Ballermann and Fouad	26369
2006 ; Ito et al. , 1999 ; Lopez-Vales et al. , 2007 ; Lu et al. , 2002 ; Boido et al.	26391
2006	26391
Ito et al. , 1999 ; Lopez-Vales et al. , 2007 ; Lu et al. , 2002 ; Boido et al.	26397
Ito	26397
et al. , 1999 ; Lopez-Vales et al. , 2007 ; Lu et al. , 2002 ; Boido et al.	26401
et al. , 1999	26401
et al.	26401
1999	26409
Lopez-Vales et al. , 2007	26415
Lopez-Vales	26415
et al. , 2007	26427
et al.	26427
2007	26435
Lu et al. , 2002	26441
Lu	26441
et al. , 2002	26444
et al.	26444
2002	26452
Boido et al.	26458
Boido	26458
et al.	26464
2009	26472
the dorsal columns and dorsolateral tissue containing the corticospinal and rubrospinal tracts	26485
the dorsal columns and dorsolateral tissue	26485
the corticospinal and rubrospinal tracts	26539
our injury model	26613
the transplanted hOECs	26631
survival or plasticity of axons	26671
survival or plasticity	26671
axons	26697
the lateral , ventrolateral and ventral parts of the cord	26706
the lateral , ventrolateral and ventral parts	26706
the cord	26754
the locomotor improvements seen	26775
the locomotor improvements	26775
3.3	26808
hOECs	26813
histological measures of injury	26827
histological measures	26827
injury	26852
controls We have shown that hOECs from olfactory mucosa reduce lesion size and cavity area within the lesion	26871
controls	26871
We	26880
hOECs from olfactory mucosa	26899
hOECs	26899
olfactory mucosa	26910
lesion size and cavity area within the lesion	26934
lesion size and cavity area	26934
the lesion	26969
This	26981
findings after transplantation of mouse mucosal OECs	27005
findings	27005
transplantation of mouse mucosal OECs	27020
transplantation	27020
mouse mucosal OECs	27039
a rat dorsolateral spinal cord injury -LRB- Ramer et al. , 2004 -RRB- , and rat olfactory bulb OECs in a moderate contusion lesion -LRB- Plant et al. , 2003 ; Takami et al. , 2002 -RRB- , but not in other studies of rat olfactory bulb OECs transplanted into contusions -LRB- Barakat et al. , 2005 ; Pearse et al. , 2007 -RRB-	27063
a rat	27063
dorsolateral spinal cord injury -LRB- Ramer et al. , 2004 -RRB- , and rat olfactory bulb OECs	27069
dorsolateral spinal cord injury -LRB- Ramer et al. , 2004 -RRB-	27069
dorsolateral spinal cord injury	27069
Ramer	27102
et al. , 2004	27108
et al.	27108
2004	27116
rat olfactory bulb OECs	27127
rat	27127
olfactory bulb OECs	27131
a moderate contusion lesion -LRB- Plant et al. , 2003 ; Takami et al. , 2002 -RRB-	27154
a moderate contusion lesion	27154
Plant	27183
et al. , 2003 ; Takami et al. , 2002	27189
et al.	27189
2003 ; Takami et al.	27197
2003	27197
Takami et al.	27203
Takami	27203
et al.	27210
2002	27218
other studies of rat olfactory bulb OECs	27236
other studies	27236
rat olfactory bulb OECs	27253
contusions -LRB- Barakat et al. , 2005 ; Pearse et al. , 2007 -RRB-	27295
contusions	27295
Barakat	27307
et al. , 2005 ; Pearse et al. , 2007	27315
et al.	27315
2005 ; Pearse et al.	27323
2005	27323
Pearse et al.	27329
Pearse	27329
et al.	27336
2007	27344
the present study	27354
the hOEC graft	27373
the host tissue	27413
H&E , in agreement with the findings of Takami	27447
H&E	27447
agreement with the findings of Takami	27455
agreement	27455
the findings of Takami	27470
the findings	27470
Takami	27486
et al. -LRB- 2002 -RRB-	27493
et al.	27493
2002	27501
fluorescence immunochemistry	27516
cavity-filling cells	27563
the hOECs	27609
the periphery of the lesion	27634
the periphery	27634
the lesion	27651
others -LRB- Barakat et al. , 2005 ; Pearse et al. , 2007 -RRB-	27678
others	27678
Barakat	27686
et al. , 2005 ; Pearse et al. , 2007	27694
et al.	27694
2005 ; Pearse et al.	27702
2005	27702
Pearse et al.	27708
Pearse	27708
et al.	27715
2007	27723
The presence of hOEC at the edge of the lesion	27730
The presence	27730
hOEC at the edge of the lesion	27746
hOEC	27746
the edge of the lesion	27754
the edge	27754
the lesion	27766
reductions in GFAP intensity	27797
reductions	27797
GFAP intensity	27811
the lesion indicating that hOECs have ameliorated the injury-induced astrogliosis	27838
the lesion	27838
hOECs	27865
the injury-induced astrogliosis	27888
coculture with astrocytes OECs reduce astrogliosis in a `` wound injury '' model -LRB- O'Toole et al. , 2007 -RRB-	27924
coculture	27924
astrocytes OECs reduce astrogliosis in a `` wound injury '' model -LRB- O'Toole et al. , 2007 -RRB-	27939
astrocytes	27939
OECs	27950
astrogliosis	27962
a `` wound injury '' model -LRB- O'Toole et al. , 2007 -RRB-	27978
a `` wound injury '' model	27978
O'Toole	28002
et al. , 2007	28010
et al.	28010
2007	28018
A previous study	28025
histological and behavioural recovery	28051
OEC transplantation	28095
the contusion injury of the spinal cord -LRB- Plant et al. , 2003 -RRB-	28120
the contusion injury	28120
the spinal cord -LRB- Plant et al. , 2003 -RRB-	28144
the spinal cord	28144
Plant	28161
et al. , 2003	28167
et al.	28167
2003	28175
That study	28182
OECs obtained from the adult rat olfactory bulb	28198
OECs	28198
the adult rat olfactory bulb	28217
similar histological recovery as shown here for hOECs from the olfactory mucosa	28252
similar histological recovery	28252
hOECs from the olfactory mucosa	28300
hOECs	28300
the olfactory mucosa	28311
Plant et al. -LRB- 2003 -RRB-	28333
Plant et al.	28333
Plant	28333
et al.	28339
2003	28347
improved locomotor ability	28367
significant axonal sparing	28411
regeneration	28439
OECs	28457
the lesion site	28485
7 days	28501
the contusion	28514
Demonstration of efficacy in contusion injuries	28529
Demonstration	28529
efficacy in contusion injuries	28546
efficacy	28546
contusion injuries	28558
an important pre-clinical outcome	28580
contusions	28622
the most common type of human injury	28637
the most common type	28637
human injury	28661
all other studies of OEC transplantation	28678
all other studies	28678
OEC transplantation	28699
either small discrete spinal cord lesions or complete spinal cord transections -LRB- Guest et al. , 2008 ; Keyvan-Fouladi et al. , 2003 ; Li et al. , 1997 ; Lopez-Vales et al. , 2007 ; Lu et al. , 2002 -RRB-	28729
either small discrete spinal cord lesions or complete spinal cord transections	28729
spinal cord lesions	28751
Guest et al. , 2008 ; Keyvan-Fouladi et al. , 2003 ; Li et al. , 1997 ; Lopez-Vales et al. , 2007 ; Lu et al. , 2002	28809
Guest	28809
et al. , 2008 ; Keyvan-Fouladi et al. , 2003 ; Li et al. , 1997 ; Lopez-Vales et al. , 2007 ; Lu et al. , 2002	28815
et al. , 2008	28815
et al.	28815
2008	28823
Keyvan-Fouladi et al. , 2003	28829
Keyvan-Fouladi	28829
et al. , 2003	28844
et al.	28844
2003	28852
Li et al. , 1997	28858
Li	28858
et al. , 1997	28861
et al.	28861
1997	28869
Lopez-Vales et al. , 2007	28875
Lopez-Vales	28875
et al. , 2007	28887
et al.	28887
2007	28895
Lu et al. , 2002	28901
Lu	28901
et al. , 2002	28904
et al.	28904
2002	28912
3.4	28919
Mechanism of hOEC action	28924
Mechanism	28924
hOEC action	28937
We	28949
significant improvements	28969
functional and histological outcomes	28997
transplantation of hOECs	29040
transplantation	29040
hOECs	29059
the contusion site	29070
there	29093
no evidence	29103
the OECs	29120
the surrounding parenchyma	29143
remyelinate	29173
axons	29209
there	29219
there	29229
evidence for axons coursing through the lesion/transplant site	29235
evidence	29235
axons coursing through the lesion/transplant site	29248
axons	29248
the lesion/transplant site	29271
We	29299
the hOECs	29316
growth factors and cytokines released into the surrounding tissues	29378
growth factors and cytokines	29378
the surrounding tissues	29421
OECs	29446
soluble factors , including neurotrophins , that promote neurite sprouting in vitro and in the injured spinal cord -LRB- Chuah et al. , 2004 ; Chung et al. , 2004 ; Woodhouse et al. , 2005 -RRB-	29459
soluble factors	29459
neurotrophins , that promote neurite sprouting in vitro and in the injured spinal cord -LRB- Chuah et al. , 2004 ; Chung et al. , 2004 ; Woodhouse et al. , 2005 -RRB-	29486
neurotrophins	29486
neurite sprouting in vitro and in the injured spinal cord -LRB- Chuah et al. , 2004 ; Chung et al. , 2004 ; Woodhouse et al. , 2005 -RRB-	29514
neurite	29514
the injured spinal cord -LRB- Chuah et al. , 2004 ; Chung et al. , 2004 ; Woodhouse et al. , 2005 -RRB-	29548
the injured spinal cord	29548
Chuah et al. , 2004 ; Chung et al. , 2004 ; Woodhouse et al. , 2005	29573
Chuah	29573
et al. , 2004 ; Chung et al. , 2004 ; Woodhouse et al. , 2005	29579
et al. , 2004	29579
et al.	29579
2004	29587
Chung et al. , 2004	29593
Chung	29593
et al. , 2004	29599
et al.	29599
2004	29607
Woodhouse et al. , 2005	29613
Woodhouse	29613
et al. , 2005	29623
et al.	29623
2005	29631
Many studies	29638
the regenerative and anti-apoptotic effects of neurotrophic factors	29669
the regenerative and anti-apoptotic effects	29669
neurotrophic factors	29716
spinal cord repair -LRB- Bregman et al. , 2002 ; Jin et al. , 2002 ; Lo et al. , 2008 ; Vavrek et al. , 2006 -RRB-	29740
spinal cord repair	29740
Bregman et al. , 2002 ; Jin et al. , 2002 ; Lo et al. , 2008 ; Vavrek et al. , 2006	29760
Bregman	29760
et al. , 2002 ; Jin et al. , 2002 ; Lo et al. , 2008 ; Vavrek et al. , 2006	29768
et al. , 2002	29768
et al.	29768
2002	29776
Jin et al. , 2002	29782
Jin	29782
et al. , 2002	29786
et al.	29786
2002	29794
Lo et al. , 2008	29800
Lo	29800
et al. , 2008	29803
et al.	29803
2008	29811
Vavrek et al. , 2006	29817
Vavrek	29817
et al. , 2006	29824
et al.	29824
2006	29832
Recent gene expression analyses	29839
OECs	29887
a large range of genes involved in wound repair , extracellular matrix formation , cell adhesion -LRB- Franssen et al. , 2008 ; Kafitz and Greer , 1998 ; Vincent et al. , 2005 -RRB- and inflammatory responses -LRB- Vincent et al. , 2005 -RRB-	29905
a large range	29905
genes involved in wound repair , extracellular matrix formation , cell adhesion -LRB- Franssen et al. , 2008 ; Kafitz and Greer , 1998 ; Vincent et al. , 2005 -RRB- and inflammatory responses -LRB- Vincent et al. , 2005 -RRB-	29922
genes involved in wound repair , extracellular matrix formation	29922
genes	29922
wound repair , extracellular matrix formation	29940
wound repair	29940
extracellular matrix formation	29954
cell adhesion -LRB- Franssen et al. , 2008 ; Kafitz and Greer , 1998 ; Vincent et al. , 2005 -RRB-	29986
cell adhesion	29986
Franssen et al. , 2008 ; Kafitz and Greer , 1998 ; Vincent et al. , 2005	30001
Franssen	30001
et al. , 2008 ; Kafitz and Greer , 1998 ; Vincent et al. , 2005	30010
et al. , 2008	30010
et al.	30010
2008	30018
Kafitz and Greer , 1998	30024
Kafitz and Greer	30024
1998	30042
Vincent et al. , 2005	30048
Vincent	30048
et al. , 2005	30056
et al.	30056
2005	30064
inflammatory responses -LRB- Vincent et al. , 2005 -RRB-	30074
inflammatory responses	30074
Vincent	30098
et al. , 2005	30106
et al.	30106
2005	30114
The reduction of astrogliosis in the hOEC transplanted animals suggests another potential mechanism of action , namely , modulation of the inflammation in the spinal cord .	30121
The reduction	30121
astrogliosis in the hOEC transplanted animals suggests another potential mechanism of action , namely , modulation of the inflammation in the spinal cord	30138
astrogliosis	30138
the hOEC transplanted animals suggests another potential mechanism of action , namely , modulation of the inflammation in the spinal cord	30154
the hOEC transplanted animals suggests another potential mechanism of action	30154
the hOEC	30154
transplanted animals	30163
another potential mechanism of action	30193
another potential mechanism	30193
action	30224
modulation of the inflammation in the spinal cord	30240
modulation	30240
the inflammation in the spinal cord	30254
the inflammation	30254
the spinal cord	30274
Inflammation	30291
an important process that removes cellular debris after injury	30307
an important process	30307
cellular debris	30341
injury	30363
activated neutrophils and macrophages/microglia	30397
activated neutrophils	30397
macrophages/microglia	30423
toxic cytokines	30469
healthy tissue	30497
secondary damage	30534
This	30552
a major problem following spinal cord injury -LRB- Fitch et al. , 1999 -RRB-	30560
a major problem	30560
spinal cord injury -LRB- Fitch et al. , 1999 -RRB-	30586
spinal cord injury	30586
Fitch	30606
et al. , 1999	30612
et al.	30612
1999	30620
The reduction of astrocytes at the lesion site	30627
The reduction	30627
astrocytes at the lesion site	30644
astrocytes	30644
the lesion site	30658
a reduced inflammatory response to the injury	30693
a reduced inflammatory response	30693
the injury	30728
the issue	30743
a deeper analysis of inflammatory cells and molecules	30762
a deeper analysis	30762
inflammatory cells and molecules	30783
example	30821
there	30830
no obvious difference in macrophage / microglia density at the lesion in the present study	30840
no obvious difference	30840
macrophage / microglia density at the lesion in the present study	30865
macrophage	30865
microglia density at the lesion in the present study	30877
microglia density	30877
the lesion in the present study	30898
the lesion	30898
the present study	30912
a timecourse analysis	30934
dynamic changes	30976
the early stages and wound and repair responses	30999
the early stages	30999
wound and repair responses	31020
Lopez-Vales et al. -LRB- 2004 -RRB- has reported an earlier higher recruitment of microglia/macrophages by rat OEC within in the first 2 weeks post-injury compared to DMEM	31048
Lopez-Vales	31048
et al. -LRB- 2004 -RRB-	31060
et al.	31060
2004	31068
an earlier higher recruitment of microglia/macrophages	31087
an earlier higher recruitment	31087
microglia/macrophages	31120
rat OEC	31145
the first 2 weeks post-injury compared to DMEM	31163
the first 2 weeks	31163
DMEM	31205
animals	31219
significant improvements	31233
function and tissue sparing	31261
Experimental procedures 4.1 .	31294
Experimental procedures	31294
4.1	31318
Biopsy and cell culture of human OECs Olfactory mucosa	31323
Biopsy and cell culture	31323
human OECs Olfactory mucosa	31350
human OECs	31350
Olfactory mucosa	31361
biopsy	31394
human volunteers	31406
routine nasal surgery -LRB- septoplasty or turbinectomy -RRB- under general anesthesia -LRB- Feron et al. , 1998 -RRB-	31430
routine nasal surgery -LRB- septoplasty or turbinectomy -RRB-	31430
routine nasal surgery	31430
septoplasty or turbinectomy	31453
septoplasty	31453
turbinectomy	31468
general anesthesia -LRB- Feron et al. , 1998 -RRB-	31488
general anesthesia	31488
Feron	31508
et al. , 1998	31514
et al.	31514
1998	31522
All biopsies	31529
informed consent using a protocol approved by the human ethics committees of Griffith University and the Brisbane Private Hospital , Brisbane , Australia , in accordance with the guidelines of the National Health and Medical Research Council of Australia	31561
informed consent	31561
a protocol approved by the human ethics committees of Griffith University and the Brisbane Private Hospital , Brisbane , Australia , in accordance with the guidelines of the National Health and Medical Research Council of Australia	31584
a protocol	31584
the human ethics committees of Griffith University and the Brisbane Private Hospital , Brisbane , Australia , in accordance with the guidelines of the National Health and Medical Research Council of Australia	31607
the human ethics committees of Griffith University and the Brisbane Private Hospital	31607
the human ethics committees	31607
Griffith University and the Brisbane Private Hospital	31638
Griffith University	31638
the Brisbane Private Hospital	31662
Brisbane , Australia , in accordance with the guidelines of the National Health	31693
Brisbane , Australia ,	31693
accordance with the guidelines of the National Health	31717
accordance	31717
the guidelines of the National Health	31733
the guidelines	31733
the National Health	31751
Medical Research Council of Australia	31775
Medical Research Council	31775
Australia	31803
The biopsies , fromthe posterior septumclose to the cribiform plate ,	31814
The biopsies	31814
fromthe posterior septumclose to the cribiform plate	31828
fromthe posterior septumclose	31828
the cribiform plate	31861
ice in Dulbecco ` smodified Eagle 's medium/Ham F12 -LRB- DMEM/F12 ; JRH -RRB- and hOECs were cultured as described -LRB- Bianco et al. , 2004 -RRB-	31909
ice	31909
Dulbecco	31916
Eagle 's medium/Ham F12 -LRB- DMEM/F12 ; JRH -RRB-	31935
Eagle 's medium/Ham F12	31935
Eagle 's	31935
DMEM/F12 ; JRH	31959
DMEM/F12	31959
JRH	31969
hOECs	31978
Bianco	32012
et al. , 2004	32019
et al.	32019
2004	32027
the	32043
tissuewas incubated for 45 min at 37 °C in Dispase II -LRB- 2.4 U/ml in Puck 's solution ; Boehringer , Mannheim , Germany -RRB- , after which the lamina propria was separated from the epithelium with a microspatula	32056
tissuewas	32056
45 min	32080
37 °C in Dispase II -LRB- 2.4 U/ml in Puck 's solution ; Boehringer , Mannheim , Germany -RRB- , after which the lamina propria was separated from the epithelium with a microspatula	32090
37 °C	32090
Dispase II -LRB- 2.4 U/ml in Puck 's solution ; Boehringer , Mannheim , Germany -RRB- , after which the lamina propria was separated from the epithelium with a microspatula	32099
Dispase II -LRB- 2.4 U/ml in Puck 's solution ; Boehringer , Mannheim , Germany -RRB-	32099
Dispase II	32099
2.4 U/ml in Puck 's solution ; Boehringer , Mannheim , Germany	32111
2.4 U/ml	32111
Puck 's solution ; Boehringer , Mannheim , Germany	32123
Puck 's solution	32123
Puck 's	32123
Boehringer , Mannheim , Germany	32140
the lamina propria	32184
the epithelium with a microspatula	32222
the epithelium	32222
a microspatula	32242
Hank 's balanced salt solution -LRB- HBSS ; JRH -RRB-	32271
Hank 's balanced salt solution	32271
Hank 's	32271
HBSS ; JRH	32302
HBSS	32302
JRH	32308
The lamina propria	32314
smaller 40 μm pieces	32351
smaller	32351
40 μm pieces	32359
a McIlwain tissue chopper -LRB- Brinkman Instruments , Inc. , Westbury , New York -RRB-	32378
a McIlwain tissue chopper	32378
Brinkman Instruments	32405
Inc. , Westbury	32427
New York	32443
collagenase -LRB- 0.25 % ; type I ; Sigma , St. Louis , MO -RRB- in DMEM/F12	32470
collagenase -LRB- 0.25 % ; type I ; Sigma , St. Louis , MO -RRB-	32470
collagenase	32470
0.25 %	32483
type I ; Sigma , St. Louis , MO	32490
type I	32490
Sigma , St. Louis , MO	32498
DMEM/F12	32523
10 min at 37 °C	32536
10 min	32536
37 °C	32545
The tissue	32551
single cells	32596
trituration	32612
HBSS	32643
The cells	32649
centrifugation	32676
DMEM/F12 supplemented with foetal calf serum -LRB- FCS , 10 % -RRB- and plated into poly-L-lysinecoated tissue culture flasks -LRB- 1 μg/cm2 ; Sigma -RRB-	32710
DMEM/F12	32710
foetal calf serum -LRB- FCS , 10 % -RRB-	32737
foetal calf serum	32737
FCS	32756
10 %	32761
poly-L-lysinecoated tissue culture flasks -LRB- 1 μg/cm2 ; Sigma -RRB-	32782
poly-L-lysinecoated tissue culture flasks	32782
1 μg/cm2 ; Sigma	32825
1 μg/cm2	32825
Sigma	32835
Cells	32843
this medium at 37 °C / 5 % CO2 for 48 h , after which the medium was changed to DMEM/F12 supplemented with neurotrophin-3 -LRB- 50 ng/ml ; Alamone Labs , Jerusalem , Israel -RRB- , a process that enhances OEC proliferation -LRB- Bianco et al. , 2004 -RRB-	32863
this medium at 37 °C / 5 % CO2 for 48 h	32863
37 °C	32878
5 % CO2 for 48	32884
5 % CO2	32884
48	32895
the medium	32913
DMEM/F12 supplemented with neurotrophin-3 -LRB- 50 ng/ml ; Alamone Labs , Jerusalem , Israel -RRB- , a process that enhances OEC proliferation -LRB- Bianco et al. , 2004 -RRB-	32939
DMEM/F12 supplemented with neurotrophin-3 -LRB- 50 ng/ml ; Alamone Labs , Jerusalem , Israel -RRB-	32939
DMEM/F12 supplemented with neurotrophin-3	32939
DMEM/F12	32939
neurotrophin-3	32966
50 ng/ml ; Alamone Labs	32982
50 ng/ml	32982
Alamone Labs	32992
Jerusalem , Israel	33006
Jerusalem	33006
Israel	33017
a process that enhances OEC proliferation -LRB- Bianco et al. , 2004 -RRB-	33026
a process	33026
OEC proliferation	33050
Bianco	33069
et al. , 2004	33076
et al.	33076
2004	33084
a cell line that overexpresses human recombinant green fluorescent protein -LRB- hrGFP -RRB-	33101
a cell line	33101
human recombinant green fluorescent protein -LRB- hrGFP -RRB-	33132
human recombinant green fluorescent protein	33132
hrGFP	33177
cells	33185
the pFB-hrGFP retroviral supernatant -LRB- Stratagene , Catalogue # 972002 -RRB-	33212
the pFB-hrGFP retroviral supernatant	33212
Stratagene , Catalogue # 972002	33250
Stratagene , Catalogue	33250
# 972002	33272
the manufacturer 's instructions	33294
the manufacturer 's	33294
Fluorescence	33327
cell sorting -LRB- FACS -RRB-	33350
cell sorting	33350
FACS	33364
a near > 99 % pure population of cells expressing hrGFP	33400
a near > 99 % pure population	33400
99 %	33408
cells expressing hrGFP	33431
cells	33431
hrGFP	33448
FACS , cultures	33461
FACS	33461
cultures	33467
approximately 80	33490
90 % confluence	33508
cyropreservation	33541
incubation in Trypsin-EDTA -LRB- 0.25 % Trypsin , 1 mM EDTA ; JRH -RRB-	33561
incubation	33561
Trypsin-EDTA -LRB- 0.25 % Trypsin , 1 mM EDTA ; JRH -RRB-	33575
Trypsin-EDTA	33575
0.25 % Trypsin	33589
0.25 %	33589
Trypsin	33595
1 mM EDTA ; JRH	33604
1 mM EDTA	33604
JRH	33615
solution	33620
5 min at 37 °C	33633
5 min	33633
37 °C	33642
5 % CO2 followed by centrifugation to pelletise the cells	33648
5 % CO2	33648
centrifugation	33667
the cells	33695
The cell pellet	33706
cryo-storage medium comprising of 90 % FCS and 10 % dimethyl sulfoxide -LRB- DMSO -RRB- at 4 °C	33746
cryo-storage medium	33746
90 % FCS and 10 % dimethyl sulfoxide -LRB- DMSO -RRB-	33780
90 % FCS	33780
10 % dimethyl sulfoxide -LRB- DMSO -RRB-	33792
10 % dimethyl sulfoxide	33792
DMSO	33816
4 °C	33825
Aliquots of cell suspension -LRB- 0.5 ml each -RRB-	33831
Aliquots of cell suspension	33831
Aliquots	33831
cell suspension	33843
0.5 ml each	33860
0.5 ml	33860
each	33867
cryotubes -LRB- Nunc -RRB-	33893
cryotubes	33893
Nunc	33904
ice	33936
liquid nitrogen for long-term storage	33963
liquid nitrogen	33963
long-term storage	33983
cryopreserved cells	34012
cryotubes	34033
liquid nitrogen	34061
a 37 °C water bath	34105
thaw after which 1 ml of pre-warmed -LRB- 37 °C -RRB- DMEM/F12 + 10 % FCS was added drop-wise to a final volume of 1.5 ml	34127
thaw	34127
1 ml of pre-warmed -LRB- 37 °C -RRB- DMEM/F12 + 10 % FCS	34144
1 ml	34144
pre-warmed -LRB- 37 °C -RRB- DMEM/F12 + 10 % FCS	34152
pre-warmed -LRB- 37 °C -RRB- DMEM/F12 + 10 %	34152
pre-warmed -LRB- 37 °C -RRB- DMEM/F12	34152
37 °C	34164
10 %	34182
a final volume of 1.5 ml	34213
a final volume	34213
1.5 ml	34231
The cell suspension	34239
10 ml of prewarmed DMEM/F12 +10 % FCS	34292
10 ml	34292
prewarmed DMEM/F12 +10 % FCS	34301
prewarmed DMEM/F12	34301
+10 % FCS	34319
200g for 10 min	34347
200g	34347
10 min	34356
The pellet	34364
DMEM/F12 +10 % FCS	34395
DMEM/F12	34395
+10 % FCS	34403
transplantation experiments	34465
hOEC cultures	34494
the University of New South Wales on the day prior to the experiment	34528
the University	34528
New South Wales on the day prior to the experiment	34546
New South Wales	34546
the day prior to the experiment	34565
the day	34565
the experiment	34582
courier	34600
ambient temperature	34611
transplantation cells	34641
the vital	34693
Trypan Blue	34707
a concentration of 15 ×	34740
a concentration	34740
15 ×	34759
104 cells/μl in DMEM/F12 +10 % FCS	34762
104 cells/μl	34762
DMEM/F12 +10 % FCS	34778
DMEM/F12	34778
+10 % FCS	34786
4.2	34796
Animals 24 inbred athymic rats -LRB- CBH-rnu/Arc , female , 8 -- 9 weeks old -RRB-	34801
Animals 24 inbred athymic rats	34801
Animals	34801
24 inbred athymic rats	34809
CBH-rnu/Arc , female	34833
CBH-rnu/Arc	34833
female	34846
8 -- 9 weeks old	34854
8	34854
9 weeks old	34856
the Animal Resources Centre -LRB- Perth , Australia -RRB-	34888
the Animal Resources Centre	34888
Perth	34917
Australia	34924
They	34936
sterilized cages equipped with an air filter and sterile beddingmaterials and maintained on 12:12-h light -- dark cycle , with free access to sterilized water and irradiated food throughout the experiment	34956
sterilized cages equipped with an air filter and sterile beddingmaterials and maintained on 12:12-h light	34956
sterilized cages	34956
an air filter and sterile beddingmaterials	34987
an air filter	34987
sterile beddingmaterials	35005
12:12-h light	35048
dark cycle , with free access to sterilized water	35062
dark cycle	35062
free access to sterilized water	35079
free access	35079
sterilized water	35094
irradiated food throughout the experiment	35115
irradiated food	35115
the experiment	35142
All animal procedures	35158
approval	35200
the University of New South Wales Animal Care and Ethics Committee	35214
the University	35214
New South Wales Animal Care and Ethics Committee	35232
New South Wales Animal Care	35232
Ethics Committee	35264
4.3	35282
Spinal cord injury Rats	35287
ketamine : xylazine -LRB- 100:10 mg/kg , IP -RRB-	35334
ketamine	35334
xylazine	35343
100:10 mg/kg	35353
IP	35367
a homeothermic blanket -LRB- body temperature maintained at 37 °C ± 1 °C -RRB-	35385
a homeothermic blanket	35385
body temperature	35409
37 °C ± 1 °C	35440
37 °C ±	35440
1 °C	35446
An incision	35453
the dorsal midline skin	35477
the mid	35506
the low thoracic region	35517
subsequent layers of connective tissue and muscle	35545
subsequent layers	35545
connective tissue and muscle	35566
the spinal column	35620
A bilateral laminectomy	35639
the T10 vertebrae	35680
Animals	35699
a moderate contusion injury	35725
the MASCIS weight drop device	35759
New York University -LRB- 12.5 mm , 10 g , -RRB-	35802
New York University	35802
12.5 mm	35823
10 g	35832
The impact height , velocity and compression	35840
the compression rate	35902
Rats	35935
the study	35959
they	35972
a compression rate	35981
more than two standard deviations from the group mean	36000
more than two standard deviations	36000
the group mean	36039
The muscles and the skin	36055
The muscles	36055
the skin	36071
layers	36103
animals	36127
antibiotics -LRB- cephalothin sodium 100 mg/mL , 0.1 ml -RRB- , analgesics -LRB- carprofen 50 mg/mL , 0.01 ml -RRB- and supplementary fluid -LRB- Hartman 's replacement solution 2 ml -RRB- twice daily for 3 days	36146
antibiotics -LRB- cephalothin sodium 100 mg/mL , 0.1 ml -RRB- , analgesics -LRB- carprofen 50 mg/mL , 0.01 ml -RRB- and supplementary fluid -LRB- Hartman 's replacement solution 2 ml -RRB-	36146
antibiotics -LRB- cephalothin sodium 100 mg/mL , 0.1 ml -RRB-	36146
antibiotics	36146
cephalothin sodium	36159
100 mg/mL , 0.1 ml	36178
100 mg/mL	36178
0.1 ml	36189
analgesics -LRB- carprofen 50 mg/mL , 0.01 ml -RRB-	36198
analgesics	36198
carprofen 50 mg/mL , 0.01 ml	36210
carprofen 50 mg/mL	36210
0.01 ml	36230
supplementary fluid -LRB- Hartman 's replacement solution 2 ml -RRB-	36243
supplementary fluid	36243
Hartman 's replacement solution 2 ml	36264
Hartman 's replacement solution	36264
Hartman 's	36264
2 ml	36295
3 days	36317
Bladders	36325
the normal voiding response	36364
Antibiotics	36402
the urine	36435
4.4	36456
hOEC transplantation	36461
One week	36482
the spinal cord contusion injury	36497
animals	36531
above and the T10 lesion site re-exposed	36563
above	36563
the T10 lesion site re-exposed	36573
the T10 lesion site	36573
The vertebral column	36605
clamps	36647
the T9 and T11 spinous process	36657
a 5-μl syringe -LRB- 26G , SGE , Australia -RRB- attached to a micromanipulater	36692
a 5-μl syringe -LRB- 26G , SGE , Australia -RRB-	36692
a 5-μl syringe	36692
26G	36708
SGE	36713
Australia	36718
a micromanipulater	36741
hOECs in solution	36779
hOECs	36779
solution	36788
the spinal cord lesion	36802
A total of 1 × 106 hOECs	36826
A total	36826
1 × 106 hOECs	36837
1 ×	36837
106 hOECs	36839
7 μl of DMEM/F12 + 10 % FCS	36867
7 μl	36867
DMEM/F12 + 10 % FCS	36875
DMEM/F12	36875
10 % FCS	36886
5 μl of hOEC solution	36895
5 μl	36895
hOEC solution	36903
the centre of the lesion over 5 min	36935
the centre	36935
the lesion over 5 min	36949
the lesion	36949
5 min	36965
1 μl	36971
1 mm rostral	36989
1 μl	37006
1 mm caudal on the midline	37024
1 mm caudal	37024
the midline	37038
a depth of 0.5 mm	37053
a depth	37053
0.5 mm	37064
Control animals	37072
the same volume of culture media	37097
the same volume	37097
culture media	37116
cells , injected into the same sites	37143
cells	37143
the same sites	37164
injection	37186
syringes	37197
place for a further 3 min	37219
place	37219
a further 3 min	37229
leakage	37255
removal	37266
4.5	37275
Behavioural assessments Each animal	37280
Behavioural assessments	37280
Each animal	37304
the open field apparatus	37338
the horizontal ladder	37382
surgery	37413
the spinal cord contusion	37432
the animals	37458
the open field apparatus at day 1 post-contusion and then weekly for 6 weeks	37487
the open field apparatus at day 1 post-contusion	37487
the open field apparatus	37487
day 1 post-contusion	37515
then weekly for 6 weeks	37540
then weekly	37540
6 weeks	37556
Animals	37565
the horizontal ladder	37593
6 weeks	37618
All sessions	37642
digital cameras linked to a FileMaker Pro database -LRB- FileMaker Pro 7.0 v3 , FileMaker Inc , 1984 -- 2007 , Ca -RRB-	37675
digital cameras linked to a FileMaker Pro database	37675
digital cameras	37675
a FileMaker Pro database	37701
FileMaker	37727
Pro 7.0 v3 , FileMaker Inc , 1984 -- 2007 , Ca	37737
Pro	37737
7.0 v3 , FileMaker Inc , 1984 -- 2007 , Ca	37741
7.0 v3	37741
FileMaker Inc	37749
1984 -- 2007	37764
Ca	37775
2 min -LRB- open field -RRB-	37783
2 min	37783
open field	37789
three passes of the horizontal ladder	37808
three passes	37808
the horizontal ladder	37824
Scoring	37847
2 independent observers blinded as to the treatment group using the digital recordings which could be analysed frame by frame when necessary	37872
2 independent observers	37872
the treatment group	37910
the digital recordings which could be analysed frame by frame when necessary	37936
the digital recordings	37936
frame by frame	37983
frame	37983
frame	37992
Averaged scores	38014
the final score for each trial	38043
the final score	38043
each trial	38063
4.5.1	38075
field assessments	38087
The BBB rating scale -LRB- Basso et al. , 1995 -RRB-	38105
The BBB rating scale	38105
Basso	38127
et al. , 1995	38133
et al.	38133
1995	38141
open field assessments	38160
this rating scale	38193
hindlimb movement	38220
a 21-point scale	38241
animals	38264
a 90-cm diameter open field	38291
The BBB rating scale	38320
ankle , knee and hip movements	38354
weight support and plantar	38400
weight support	38400
plantar	38419
limb movements , paw rotation and trunk stability	38461
limb movements	38461
paw rotation	38477
trunk stability	38494
Animals	38511
the first day	38536
contusion surgery	38556
consistency of the lesion	38586
consistency	38586
the lesion	38601
weekly	38636
Animals	38644
the study	38671
their BBB score at day 1	38684
their BBB score	38684
day 1	38703
greater than two standard deviations from the group mean	38713
greater than two standard deviations	38713
the group mean	38755
4.5.2	38771
Horizontal ladder rung walking test For a more challenging assessment of hindlimb function rats	38778
Horizontal ladder	38778
test	38809
a more challenging assessment of hindlimb function rats	38818
a more challenging assessment	38818
hindlimb function rats	38851
a horizontal ladder rung walking apparatus using the methods described by Metz and Whishaw -LRB- 2002 -RRB-	38894
a horizontal ladder	38894
apparatus	38927
the methods described by Metz and Whishaw -LRB- 2002 -RRB-	38943
the methods described by Metz and Whishaw	38943
the methods	38943
Metz and Whishaw	38968
2002	38986
Two 100-cm perspex sheets	38993
the side walls of the apparatus which were separated by 10 cm and connected at their bases by a series of 3 mm metal rungs set in an irregular pattern	39031
the side walls	39031
the apparatus which were separated by 10 cm and connected at their bases by a series of 3 mm metal rungs set in an irregular pattern	39049
the apparatus	39049
10 cm	39087
their bases	39110
a series of 3 mm metal rungs set in an irregular pattern	39125
a series	39125
3 mm metal rungs set in an irregular pattern	39137
3 mm metal rungs	39137
an irregular pattern	39161
The ladder	39183
a height of 20 cm	39210
a height	39210
20 cm	39222
a mirror angled at 45 ° to provide a ventral view of the hindlimbs	39234
a mirror	39234
45 °	39253
a ventral view of the hindlimbs	39268
a ventral view	39268
the hindlimbs	39286
A dark home cage	39301
the end of the ladder	39335
the end	39335
the ladder	39346
locomotion	39370
Performance	39382
a 7 - category scale	39411
a 7	39411
category scale	39416
each step	39436
the foot placement on the rung	39446
the foot placement	39446
the rung	39468
the	39468
its position and placement accuracy	39500
0	39538
Total miss , -LRB- 1 -RRB- Deep slip , -LRB- 2 -RRB- Slight slip , -LRB- 3 -RRB- Replacement , -LRB- 4 -RRB- Correction , -LRB- 5 -RRB- Partial placement and -LRB- 6 -RRB- Correct placement	39541
Total miss	39541
Total	39541
-LRB- 1 -RRB- Deep slip , -LRB- 2 -RRB- Slight slip , -LRB- 3 -RRB- Replacement , -LRB- 4 -RRB- Correction , -LRB- 5 -RRB- Partial placement and -LRB- 6 -RRB- Correct placement	39553
Deep	39557
slip ,	39562
slip	39562
-LRB- 2 -RRB- Slight slip , -LRB- 3 -RRB- Replacement , -LRB- 4 -RRB- Correction , -LRB- 5 -RRB- Partial placement and -LRB- 6 -RRB- Correct placement	39568
-LRB- 2 -RRB- Slight slip , -LRB- 3 -RRB- Replacement , -LRB- 4 -RRB- Correction , -LRB- 5 -RRB- Partial placement	39568
Slight	39572
slip , -LRB- 3 -RRB- Replacement , -LRB- 4 -RRB-	39579
slip , -LRB- 3 -RRB- Replacement ,	39579
slip	39579
-LRB- 3 -RRB- Replacement	39585
4	39603
Correction , -LRB- 5 -RRB- Partial placement	39606
Correction	39606
-LRB- 5 -RRB- Partial placement	39618
Partial placement	39622
-LRB- 6 -RRB- Correct placement	39644
6	39645
Scores of 0 , 1 or 2	39667
Scores	39667
0 , 1 or 2	39677
` errors '' , i.e. an error represented a total miss or any type of foot slip	39703
` errors '' , i.e. an error represented a total miss	39703
` errors ''	39703
i.e. an error represented a total miss	39713
i.e.	39713
an error	39718
a total	39739
any type of foot slip	39755
any type	39755
foot slip	39767
The percentage of steps with errors	39778
The percentage	39778
steps with errors	39796
steps	39796
errors	39807
each animal	39833
3 passes of the apparatus	39852
3 passes	39852
the apparatus	39864
the group	39895
4.6	39906
Histological analysis Six weeks afterhOECtransplantation	39911
Histological analysis	39911
Six weeks	39933
each animal	39968
sodium pentobarbitone -LRB- Lethobarb ; 0.15 ml/100 g , IP -RRB-	39998
sodium pentobarbitone	39998
Lethobarb ; 0.15 ml/100 g , IP	40021
Lethobarb	40021
0.15 ml/100 g , IP	40032
0.15 ml/100 g	40032
IP	40047
physiological saline	40084
4 % paraformaldehyde in 0.1 M phosphate buffer -LRB- pH 7.4 -RRB-	40118
4 % paraformaldehyde	40118
0.1 M phosphate buffer -LRB- pH 7.4 -RRB-	40141
0.1 M phosphate buffer	40141
pH 7.4	40165
A segment of spinal cord extending 5 mm rostral and caudal to the injury site	40174
A segment	40174
spinal cord extending 5 mm rostral and caudal to the injury site	40187
spinal cord	40187
5 mm	40209
rostral and caudal to the injury site	40213
rostral and caudal	40213
the injury site	40235
The tissue	40266
the same fixative for 2 h	40295
the same fixative	40295
2 h	40317
a solution of 30 % sucrose	40347
a solution	40347
30 % sucrose	40361
0.1 M phosphate buffer	40376
0.01 % sodium azide until sectioning	40404
0.01 % sodium azide	40404
sectioning	40430
Sections	40442
a thickness of 30 μm	40463
a thickness	40463
30 μm	40478
the dorsal	40489
ventral surface of the spinal cord -LRB- approx 1.8 mm in total depth -RRB-	40503
ventral surface	40503
the spinal cord -LRB- approx 1.8 mm in total depth -RRB-	40522
the spinal cord	40522
1.8 mm in total depth	40546
1.8 mm	40546
total depth	40555
All the sections	40569
a series of 10	40602
a series	40602
10	40614
adjacent sections	40625
consecutive slides	40651
Each slide	40671
6 -- 7 sections of spinal cord	40702
6	40702
7 sections of spinal cord	40704
7 sections	40704
spinal cord	40718
300-μm intervals	40733
the dorsal to ventral surface	40755
the dorsal	40755
ventral surface	40769
each animal	40790
spinal cord sections	40803
the central canal	40856
each cord	40878
5 dorsal	40907
ventral sections	40919
some animals	40941
the very dorsal and/or the very ventral sections	40954
very dorsal	40958
the very ventral sections	40977
these	41024
the analysis	41049
One slide	41063
haematoxylin and eosin -LRB- H&E -RRB-	41090
haematoxylin and eosin	41090
H&E	41114
one	41120
Fluromount -LRB- Dako -RRB- for examination of hOECs	41139
Fluromount -LRB- Dako -RRB-	41139
Fluromount	41139
Dako	41151
examination of hOECs	41161
examination	41161
hOECs	41176
GFP	41193
Three other slides	41198
immunohistochemistry for GFAP , NF200 and ED1	41231
immunohistochemistry	41231
GFAP , NF200 and ED1	41256
Sections	41277
phosphate buffered saline with triton-X -LRB- PBST -RRB- for 10 min and in 5 % normal goat serum for 30 min before overnight incubation in primary antibody at 4 °C ; Rabbit anti-GFAP -LRB- 1/1000 , Dako , Denmark -RRB- , Mouse anti-Neurofilament 200 -LRB- 1/1000 , Sigma , MO -RRB- and Rabbit anti-ED1 -LRB- 1/2000 , AbD Serotec , UK -RRB-	41304
phosphate	41304
saline with triton-X -LRB- PBST -RRB- for 10 min and in 5 % normal goat serum for 30 min	41323
saline	41323
triton-X -LRB- PBST -RRB- for 10 min	41335
triton-X -LRB- PBST -RRB-	41335
triton-X	41335
PBST	41345
10 min	41355
5 % normal goat serum	41369
30 min	41394
overnight incubation in primary antibody	41408
overnight incubation	41408
primary antibody	41432
4 °C ; Rabbit anti-GFAP -LRB- 1/1000 , Dako , Denmark -RRB- , Mouse anti-Neurofilament 200 -LRB- 1/1000 , Sigma , MO -RRB- and Rabbit anti-ED1 -LRB- 1/2000 , AbD Serotec , UK -RRB-	41452
4 °C	41452
Rabbit anti-GFAP -LRB- 1/1000 , Dako , Denmark -RRB- , Mouse anti-Neurofilament 200 -LRB- 1/1000 , Sigma , MO -RRB- and Rabbit anti-ED1 -LRB- 1/2000 , AbD Serotec , UK -RRB-	41458
Rabbit anti-GFAP -LRB- 1/1000 , Dako , Denmark -RRB-	41458
Rabbit anti-GFAP	41458
1/1000	41476
Dako	41484
Denmark	41490
Mouse anti-Neurofilament 200 -LRB- 1/1000 , Sigma , MO -RRB-	41500
Mouse anti-Neurofilament 200	41500
Mouse	41500
200	41525
1/1000	41530
Sigma	41538
MO	41545
Rabbit anti-ED1 -LRB- 1/2000 , AbD Serotec , UK -RRB-	41553
Rabbit anti-ED1	41553
1/2000	41570
AbD Serotec	41578
UK	41591
Sections	41596
3 changes of PBST	41620
3 changes	41620
PBST	41633
incubation in either AF 568-conjugated Goat anti-mouse IgG -LRB- 1/200 , Molecular Probes , Invitrogen , CA -RRB- , or TRITC-conjugated Swine anti-rabbit IgG antibody -LRB- 1/200 , Dako , Denmark -RRB-	41645
incubation	41645
either AF 568-conjugated Goat anti-mouse IgG -LRB- 1/200 , Molecular Probes , Invitrogen , CA -RRB- , or TRITC-conjugated Swine anti-rabbit IgG antibody -LRB- 1/200 , Dako , Denmark -RRB-	41659
either AF 568-conjugated Goat anti-mouse IgG -LRB- 1/200 , Molecular Probes , Invitrogen , CA -RRB- , or TRITC-conjugated Swine anti-rabbit IgG antibody	41659
AF 568-conjugated Goat anti-mouse IgG -LRB- 1/200 , Molecular Probes , Invitrogen , CA -RRB-	41666
AF 568-conjugated Goat	41666
anti-mouse IgG -LRB- 1/200 , Molecular Probes , Invitrogen , CA -RRB-	41689
anti-mouse IgG	41689
1/200	41705
Molecular Probes	41712
Invitrogen , CA	41730
TRITC-conjugated Swine	41750
1/200	41799
Dako	41806
Denmark	41812
1 h at room temperature	41825
1 h	41825
room temperature	41832
All sections	41850
Hoechst -LRB- 33342 , Invitrogen , CA -RRB- for 10 min	41888
Hoechst -LRB- 33342 , Invitrogen , CA -RRB-	41888
Hoechst	41888
33342	41897
Invitrogen	41904
CA	41916
10 min	41924
the cell nuclei	41944
Sections	41961
3 changes of PBST and cover	41990
3 changes	41990
PBST and cover	42003
Fluromount mounting	42032
media -LRB- Dako , Denmark -RRB-	42052
media	42052
Dako	42059
Denmark	42065
4.6.1	42075
Lesion size Low-power digital images of the H&E	42082
Lesion size Low-power digital images	42082
the H&E	42122
sections -LRB- Fig. 2 -RRB-	42138
sections	42138
Fig. 2	42148
injury quantification	42170
Each section	42193
a PixelLink video camera	42225
an Olympus BH-2 microscope	42261
One observer	42289
the group	42314
all the measurements	42329
Image J	42356
analysis software -LRB- Rasband , 1997 -- 2009 -RRB-	42364
analysis software	42364
Rasband , 1997 -- 2009	42383
Rasband	42383
1997 -- 2009	42392
The following measurements	42404
each horizontal section	42444
the spinal cord area , measured in a 5 mmlength of tissue	42469
the spinal cord area	42469
a 5 mmlength of tissue	42503
a 5 mmlength	42503
tissue	42519
the epicenter of the lesion -LRB- thick dashed lines in Fig. 2 -RRB- and the lesion area , defined by the area of extensive tissue disruption , loss of neurons , and a rim of pale staining tissue -LRB- thin dashed lines in Fig. 2 -RRB-	42537
the epicenter of the lesion	42537
the epicenter	42537
the lesion	42554
lines in Fig. 2	42579
lines	42579
Fig. 2	42588
the lesion area , defined by the area of extensive tissue disruption , loss of neurons , and a rim of pale staining tissue -LRB- thin dashed lines in Fig. 2 -RRB-	42600
the lesion area , defined by the area of extensive tissue disruption , loss of neurons , and a rim of pale staining tissue	42600
the lesion area	42600
the area of extensive tissue disruption , loss of neurons , and a rim of pale staining tissue	42628
the area of extensive tissue disruption	42628
the area	42628
extensive tissue disruption	42640
loss of neurons	42669
loss	42669
neurons	42677
a rim of pale staining tissue	42690
a rim	42690
pale staining tissue	42699
lines in Fig. 2	42733
lines	42733
Fig. 2	42742
High power microscopy	42751
tissue injury ; cavity areas within the lesion , which were non-cellular areas selected by grey scale intensity using Image J software	42792
tissue injury	42792
cavity areas within the lesion , which were non-cellular areas selected by grey scale intensity using Image J software	42807
cavity areas	42807
the lesion , which were non-cellular areas selected by grey scale intensity using Image J software	42827
the lesion	42827
non-cellular areas selected by grey scale intensity using Image J software	42850
non-cellular areas	42850
grey scale intensity using Image J software	42881
grey scale intensity	42881
Image J software	42908
the width of the spinal cord at a line drawn perpendicular to the midline at the epicenter of the lesion and the width of spared tissue on the same line as above , with the left and right sides summed	42944
the width of the spinal cord at a line drawn perpendicular to the midline at the epicenter of the lesion	42944
the width	42944
the spinal cord at a line drawn perpendicular to the midline at the epicenter of the lesion	42957
the spinal cord	42957
a line drawn perpendicular to the midline at the epicenter of the lesion	42976
a line	42976
the midline	43006
the epicenter of the lesion	43021
the epicenter	43021
the lesion	43038
the width of spared tissue on the same line as above , with the left and right sides summed	43053
the width	43053
tissue	43073
the same line	43083
the left and right sides	43112
Measurements	43145
the percentage of lesion area in the spinal cord area , the percentage of cavity area in the lesion area , and the percentage of spared tissue in the width of the spinal cord	43176
the percentage of lesion area in the spinal cord area	43176
the percentage	43176
lesion area in the spinal cord area	43194
lesion area	43194
the spinal cord area	43209
the percentage of cavity area in the lesion area	43231
the percentage	43231
cavity area in the lesion area	43249
cavity area	43249
the lesion area	43264
the percentage of spared tissue in the width of the spinal cord	43285
the percentage	43285
spared tissue in the width of the spinal cord	43303
spared tissue	43303
the width of the spinal cord	43320
the width	43320
the spinal cord	43333
4.6.2	43350
Immunohistochemistry hOECs	43357
strong green fluorescence	43394
All other immunohistochemistry	43421
red fluorescent secondary antibodies	43474
GFAP staining intensity	43512
a mean grey scale value using NIH Image	43552
a mean grey scale value	43552
NIH Image	43582
The increase in GFAP intensity	43593
The increase	43593
GFAP intensity	43609
the lesion	43636
the mean grayscale value of GFAP staining	43667
the mean grayscale value	43667
GFAP staining	43695
the lesion divided by the mean grayscale value of GFAP staining 5 mm distal to the lesion	43721
the lesion	43721
the mean grayscale value of GFAP staining 5 mm distal	43743
the mean grayscale value	43743
GFAP staining 5 mm distal	43771
GFAP staining	43771
5 mm	43785
the lesion	43800
The percentage increase in GFAP intensity in each spinal cord	43812
The percentage increase	43812
GFAP intensity in each spinal cord	43839
GFAP intensity	43839
each spinal cord	43857
each group at each level of spinal cord tissue	43891
each group	43891
each level of spinal cord tissue	43905
each level	43905
spinal cord tissue	43919
Sections of uninjured spinal cord	43939
Sections	43939
uninjured spinal cord	43951
no differences	43980
GFAP staining intensity	43998
the section using this method	44029
the section	44029
this method	44047
Primary antibody	44060
negative controls	44093
Sections stained with NF200	44112
Sections	44112
NF200	44134
confocal microscopy	44160
hOECs	44196
NF 200 positive axon profiles	44225
NF 200	44225
Antibodies against ED1	44256
Antibodies	44256
ED1	44275
macrophage/microglia infiltration	44300
4.7	44335
Statistical methods	44340
the open field test , two way ANOVA	44364
the open field test	44364
two way ANOVA	44385
measures	44408
BBB scores	44437
the hOEC transplanted and control groups over the 6-week period with Boneronni post hoc tests	44452
the hOEC transplanted	44452
control groups over the 6-week period with Boneronni post hoc tests	44478
control groups	44478
the 6-week period with Boneronni post hoc tests	44498
the 6-week period	44498
Boneronni post hoc tests	44521
the horizontal ladder test and histological measurements	44551
the horizontal ladder test	44551
histological measurements	44582
t-tests	44609
the groups	44638
6 weeks post contusion	44652
6 weeks	44652
The statistical packages SPSS v17 .0 -LRB- SPSS released 23/08/08 , Chicago , SPSS Inc. -RRB- and Prism 5 -LRB- GraphPad Software , Inc , CA -RRB- were used for statistical analysis and α = 0.05	44676
The statistical packages SPSS v17 .0 -LRB- SPSS released 23/08/08 , Chicago , SPSS Inc. -RRB-	44676
The statistical packages SPSS v17 .0	44676
The statistical packages	44676
SPSS v17 .0	44701
SPSS released 23/08/08 , Chicago , SPSS Inc.	44713
SPSS	44713
23/08/08 , Chicago , SPSS Inc.	44727
23/08/08	44727
Chicago , SPSS Inc.	44737
Chicago	44737
SPSS Inc.	44746
Prism 5 -LRB- GraphPad Software , Inc , CA -RRB- were used for statistical analysis and α = 0.05	44761
Prism 5	44761
GraphPad Software	44770
Inc	44789
CA	44794
statistical analysis and α = 0.05	44812
statistical analysis and α	44812
0.05	44839
the criterion for statistical significance	44856
the criterion	44856
statistical significance	44874
